Ocular melanin binding of drugs : in vitro binding studies combined to a pharmacokinetic model by Rimpelä, Anna-Kaisa
  
 
 
 
 
 
 
 
 
 
OCULAR MELANIN BINDING OF DRUGS:  IN VITRO BINDING STUDIES 
COMBINED TO A PHARMACOKINETIC MODEL 
 
 
 
 
 
 
 
 
 
 
 
    Anna-Kaisa Rimpelä 
    University of Helsinki 
    Faculty of Pharmacy 
Division of Pharmaceutical 
Biosciences 
 
February 2014 
 
  
Tiedekunta/Osasto  Fakultet/Sektion – Faculty 
 Faculty of Pharmacy 
Laitos/Institution– Department 
Division of Pharmaceutical Biosciences 
Tekijä/Författare – Author 
 Anna-Kaisa Rimpelä 
Työn nimi / Arbetets titel – Title 
Ocular melanin binding of drugs: in vitro binding studies combined to a 
pharmacokinetic model 
Oppiaine /Läroämne – Subject 
Biopharmacy 
Työn laji/Arbetets art – Level 
Master’s thesis 
Aika/Datum – Month and year 
February 2014 
Sivumäärä/ Sidoantal – Number of pages 
85 (+appendices) 
Tiivistelmä/Referat – Abstract 
Certain drugs accumulate into pigmented tissues due to their binding to melanin, a 
macromolecule inside pigmented cells. Melanin can affect the drug’s pharmacokinetics 
by acting as a drug reservoir. Binding can also cause toxic effects by accumulating 
compounds to pigmented cells. This thesis focuses on ocular melanin. The literature 
review covers the most common methods used in the study of ocular melanin binding 
and concentrates on in vitro methods and the analysis and usability of the results in 
pharmacokinetic modeling. 
 
The aim of the experimental part was to study melanin binding of a set of compounds 
in vitro with melanin isolated from the retinal pigment epithelium (RPE) and choroid of 
porcine eyes and with primary porcine RPE cells and then construct a pharmacokinetic 
model of melanin binding with STELLA® software and simulate it with the in vitro 
results. The compounds chosen for the study; nadolol, timolol, chloroquine, 
methotrexate, carboxydichlorofluorescein (CDCF) and dexamethasone, are small 
molecules with diverse physicochemical properties (octanol/water partitioning 
coefficient (logP), pKa, acid/base status). Some are also efflux substrates. The in vitro 
binding with melanin was studied at pH 7.4 and in addition at pH 5 for the acidic 
compounds, since the pH inside melanosomes where melanin is located is acidic. 
Porcine RPE cells were used to study the amount of uptake and rate of elimination of 
the set of compounds. The effect of efflux was also evaluated with a general efflux 
inhibitor probenecid. 
 
All the basic compounds bound to melanin in vitro. The acidic compounds did not seem 
to bind at pH 7.4 but bound at pH 5. Chloroquine, as expected, had the highest 
binding. In the cell studies, the uptake of chloroquine was significant, at least partly due 
to melanin binding. The other compounds were taken into the cells to a much smaller 
extent. The efflux inhibitor did not seem to affect the results. The results of the binding 
study were used in the models constructed of melanin binding and cellular 
pharmacokinetics. The constructed model was a very simple one not taking into 
account many factors affecting cellular pharmacokinetics. The results of both the in 
vitro studies and the model give a good idea of the importance of melanin binding in 
ocular drug delivery. The model can be used in the future as a base for more 
comprehensive models of the effect of melanin binding on ocular pharmacokinetics. 
Avainsanat – Nyckelord – Keywords 
Ocular pigment, melanin binding, in vitro studies, pharmacokinetic modeling  
Säilytyspaikka – Förvaringställe – Where deposited 
Division of Pharmaceutical Biosciences 
Muita tietoja – Övriga uppgifter – Additional information 
Supervisors: Heidi Kidron, Arto Urtti 
  
Tiedekunta/Osasto  Fakultet/Sektion – Faculty 
Farmasian tiedekunta 
Laitos/Institution– Department 
Farmaseuttisten biotieteiden osasto 
Tekijä/Författare – Author 
Anna-Kaisa Rimpelä 
Työn nimi / Arbetets titel – Title 
Lääkeaineiden sitoutuminen silmän melaniiniin: in vitro –kokeet yhdistettynä 
farmakokineettiseen malliin 
Oppiaine /Läroämne – Subject 
Biofarmasia 
Työn laji/Arbetets art – Level 
 Pro gradu 
Aika/Datum – Month and year 
 Helmikuu 2014 
Sivumäärä/ Sidoantal – Number of pages 
 85 (+liitteet) 
Tiivistelmä/Referat – Abstract 
 
Lääkeaineet voivat kerääntyä pigmentoituneisiin kudoksiin sitoutumalla solujen 
sisältämään melaniinipigmenttiin. Melaniini vaikuttaa lääkeaineen farmakokinetiikkaan 
toimimalla varastona, josta lääkeaine annostelun päättymisen jälkeen vapautuu. 
Sitoutuminen voi myös aiheuttaa haittoja suuren paikallisen pitoisuuden vuoksi. Tämä 
tutkimus käsittelee silmän melaniinia. Kirjallisuuskatsauksessa tutustutaan 
tavallisimpiin melaniinisitoutumisen tutkimusmenetelmiin ja painotetaan in vitro 
sitoutumiskokeita ja tulosten sopivuutta farmakokineettiseen mallinnukseen.  
 
Kokeellisen tutkimuksen tavoitteena oli tutkia muutaman yhdisteen sitoutumista sian 
silmän verkkokalvon pigmenttiepiteelistä (RPE) ja suonikalvosta eristettyyn melaniiniin 
sekä lääkeaineiden kinetiikkaa sian RPE:n primaarisoluilla ja yhdistää tulokset 
STELLA® -ohjelmalla rakennettuun kineettiseen malliin melaniinisitoutumisesta. 
Tutkittavaksi valittiin yhdisteitä, joilla on erilaiset fysikokemialliset ominaisuudet 
(oktanoli/vesi -jakautumiskerroin (logP), pKa, happo/emäs). Osa oli myös 
efluksitransporttereiden substraatteja. Kaikkien yhdisteiden melaniinisitoutuminen 
tutkittiin pH:ssa 7,4 ja happamilla molekyyleillä lisäksi pH:ssa 5, sillä melanosomit eli 
melaniinia sisältävät soluelimet ovat sisällöltään happamia. Solukokeissa mitattiin 
soluun menevää ainemäärää ja eliminaatiota soluista. Efluksitransporttereiden 
vaikutusta tutkittiin yleisellä inhibiittorilla (probenesidi). 
 
Kaikki emäksiset yhdisteet sitoutuivat melaniiniin. Happamat yhdisteet eivät sitoutuneet 
pH:ssa 7,4, mutta sitoutuivat pH:ssa 5. Klorokiini sitoutui odotetusti parhaiten. 
Solukokeissa se oli myös ainut yhdiste, jota meni merkittävästi solun sisään. Tämä 
johtui osittain melaniinisitoutumisesta. Efluksi-inhibiittori ei näyttänyt vaikuttavan 
tuloksiin. Sitoutumiskokeen tuloksia käytettiin rakennetussa farmakokineettisessä 
mallissa. Mallit rakennettiin sekä melaniinisitoutumisesta että solutason kinetiikasta. 
Solumalli oli erittäin yksinkertainen, mutta sitä voidaan hyödyntää rakennettaessa 
kattavampia malleja melaniinisitoutumisen vaikutuksesta lääkeaineen 
farmakokinetiikkaan silmässä. Tutkimus kokonaisuudessaan osoitti 
melaniinisitoutumisen tärkeyden lääkeaineiden annostelussa silmään.  
 
Avainsanat – Nyckelord – Keywords 
Silmän pigmentti, melaniinisitoutuminen, in vitro -kokeet, farmakokineettinen mallinnus 
Säilytyspaikka – Förvaringställe – Where deposited 
Farmaseuttisten biotieteiden osasto 
Muita tietoja – Övriga uppgifter – Additional information 
Ohjaajat: Heidi Kidron, Arto Urtti 
 
  
TABLE OF CONTENTS 
 
1 INTRODUCTION ..................................................................................................... 1 
2 MELANIN ................................................................................................................. 3 
2.1 Melanin synthesis ............................................................................................... 3 
2.2 Melanin in ocular tissues .................................................................................... 6 
2.2.1 Retinal pigment epithelium ......................................................................... 7 
2.2.2 Uveal melanin ............................................................................................. 8 
2.3 Binding of drugs to melanin ............................................................................. 11 
3 METHODS FOR STUDYING MELANIN BINDING .......................................... 13 
3.1 In vitro studies with melanin ............................................................................ 13 
3.1.1 Binding parameters of in vitro studies ...................................................... 14 
3.1.2 Melanin sources for in vitro studies .......................................................... 19 
3.1.3 Affinity chromatography .......................................................................... 22 
3.2 In vitro studies with melanosomes ................................................................... 23 
3.3 Ex vivo studies .................................................................................................. 25 
3.4 In vivo studies ................................................................................................... 27 
3.5 Cell models of melanin binding ....................................................................... 28 
4 PREDICTION OF MELANIN BINDING .............................................................. 30 
5 AIMS OF THE STUDY .......................................................................................... 32 
6 MATERIALS AND METHODS ............................................................................ 33 
6.1 Materials ........................................................................................................... 33 
6.2 In vitro binding studies with melanin............................................................... 34 
6.2.1  Isolation of melanin granules .................................................................... 34 
6.2.2 Characterization of melanin granules ....................................................... 34 
6.2.3 Binding study ............................................................................................ 35 
6.2.4 Sample analysis ......................................................................................... 38 
6.2.5  Calculation of the binding parameters ...................................................... 39 
6.3 Cell study with porcine RPE cells .................................................................... 40 
6.3.1 Isolation of RPE cells from porcine eyes .................................................. 40 
6.3.2 Cell culture ................................................................................................ 41 
6.3.3 Cell experiments ....................................................................................... 41 
6.4 Pharmacokinetic modeling ............................................................................... 43 
7 RESULTS ................................................................................................................ 45 
7.1 Characterization of melanin granules ............................................................... 45 
7.2 Binding study ................................................................................................... 47 
  
7.2.1 Kinetic study ............................................................................................. 47 
7.2.2 Equilibrium study ..................................................................................... 47 
7.2.3 Dissociation study ..................................................................................... 51 
7.2.4 Association study ...................................................................................... 53 
7.3 Cell study ......................................................................................................... 53 
7.3.1 Cell culture ................................................................................................ 53 
7.3.2 Uptake study ............................................................................................. 54 
7.3.3 Elimination study ...................................................................................... 55 
7.4 Pharmacokinetic modeling ............................................................................... 58 
7.4.1 Modeling of melanin binding ................................................................... 58 
7.4.2 Modeling of cell uptake with melanin binding ......................................... 61 
8 DISCUSSION .......................................................................................................... 63 
8.1 Characterization of melanin granules ............................................................... 63 
8.2 Binding study ................................................................................................... 64 
8.2.1 Experimental conditions ........................................................................... 64 
8.2.2 Results of the binding study ...................................................................... 67 
8.3 Cell study ......................................................................................................... 70 
8.4 Pharmacokinetic modeling ............................................................................... 72 
8.4.1 Melanin binding model ............................................................................. 72 
8.4.2 Cell model ................................................................................................. 74 
8.5 Future perspectives ........................................................................................... 76 
9 CONCLUSIONS ..................................................................................................... 77 
REFERENCES ............................................................................................................... 78 
 
 
APPENDIX 1. Formulations of PBS and citrate buffer.  
APPENDIX 2. Microscope images of melanin granules in suspension.  
APPENDIX 3. Results of the kinetic study.  
APPENDIX 4. Cell uptake of chloroquine.  
APPENDIX 5. STELLA
®
 models.  
APPENDIX 6. Melanin binding model: time course of binding.  
APPENDIX 7. Cell model: uptake.  
 
  
ABBREVIATIONS 
 
AMD age related macular degeneration 
APS aminopropyl silica 
BCRP breast cancer resistance protein 
BN brown Norway (rat) 
CaCl2  calcium chloride 
CDCF carboxydichlorofluorescein 
DHI 5,6-dihydroxyindole 
DHICA 5,6-dihydroxyindole-2-carboxylic 
DMSO dimethyl sulfoxide 
DOPA dihydroxyphenylalanine 
DPBS Dulbecco’s phosphate buffered saline 
DT integration interval (STELLA
®
 software) 
D-MEM Dulbecco’s modified eagle medium 
EDTA ethylenediaminetetraacetate 
FBS fetal bovine serum 
HPLC high performance liquid chromatography 
IPE iris pigment epithelium 
logP octanol/water partitioning coefficient 
MgCl2 magnesium chloride 
MRP multidrug resistance protein 
MTX methotrexate 
PBS phosphate buffered saline 
PET positron emission tomography 
pRPE porcine retinal pigment epithelium 
P-gp P-glycoprotein 
QSPR quantitative structure-property relationship 
QSRR quantitative structure-retention relationship 
RPE retinal pigment epithelium 
SPECT single photon emission computed tomography 
TLSER theoretical linear solvation energy relationship 
  
UPLC ultra-performance liquid chromatography 
UV ultraviolet 
WBA whole body autoradiography 
 
 
1 
 
1 INTRODUCTION 
 
The accumulation of certain drugs to pigmented tissues has been acknowledged for long 
(Potts 1962; Potts 1964a). This accumulation is caused by the binding of drugs to 
melanin, a macromolecule inside pigmented cells. Pigmented cells are found in many 
tissues of the body including the skin, hair, the brain, the inner ear, and the eye. Melanin 
affects the pharmacokinetics of a drug by retaining the drug inside pigmented cells and 
by releasing it when dosing has ended. Thus the binding is a factor to be considered in 
drug delivery. This thesis will concentrate on ocular melanin binding and ocular drug 
delivery. 
 
In the eye, melanin containing tissues include the iris, ciliary body, sclera, choroid and 
retinal pigment epithelium (RPE) (Ings 1984; Durairaj et al. 2012). Ocular drug delivery 
can be implemented via various routes depending on the target tissue (Figure 1). In 
diseases of the anterior part of the eye, the drug is most commonly delivered topically 
as eye drops or formulations with a more prolonged action (Urtti 2006). From the 
surface of the eye the drug can penetrate the corneal epithelium to reach the aqueous 
humor (Figure 1 (1)) and then the iris and ciliary body, which are melanin containing 
tissues. It can also penetrate the conjunctival epithelium and the sclera to reach the 
ciliary body (2) and come to contact with melanin again. Reaching the posterior part of 
the eye with topical administration is difficult. When the target tissue is in the posterior 
part, the drug can be delivered periocularly, by injecting or implanting the drug onto the 
surface of the sclera (3). In that case, the drug has to penetrate the sclera and depending 
on the target tissue the ciliary body or the choroid and the RPE, all containing melanin. 
RPE and retinal vascular endothelium (capillaries) are cell layers with tight junctions 
and are part of the blood-retinal-barrier, thus constituting a strong barrier for drug 
delivery. The drug also needs to cross this barrier when it is delivered to the eye 
systemically (4).  Another method to deliver the drug to the posterior part is intravitreal 
injection. This is the most common route for treating posterior part diseases. The drug is 
distributed from the vitreous to the surrounding ocular tissues and has again access to 
melanin in the RPE, ciliary body and even iris. Therefore it can accumulate into these 
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tissues. The highest melanin content of ocular tissues is in the RPE-choroid and it poses 
a significant barrier and reservoir for ocular drugs (Menon et al. 1992).  
 
 
 
Figure 1. Routes and barriers of ocular drug delivery: topical administration (1, 2), 
periocular administration (3) and systemic delivery (4). In addition, intravitreal 
injection, where the drug is administered into the vitreous humor, can be used. 
(Modified from Urtti 2006) 
 
Melanin binding of drugs has been studied in vivo and in vitro (Ings 1984). The extent 
of melanin binding of many ocular drugs has been investigated and some quantitative 
structure-property relationship models of melanin binding have been created but 
pharmacokinetic modeling of melanin binding has never been done. The existing 
pharmacokinetic models of ocular drug delivery do not take into account the effect of 
melanin binding in detail (Ranta and Urtti 2006; Ranta et al. 2010). Melanin binding is 
included into the models only via its contribution to measured parameters like the lag 
time in permeability of melanin containing tissue layers but no individual parameters 
for melanin binding have been addressed. Creating a pharmacokinetic model of melanin 
binding and including it into a model of ocular drug delivery would be beneficial for 
drug discovery as well as a better understanding of the effect of melanin on ocular 
pharmacokinetics. 
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2 MELANIN 
 
2.1 Melanin synthesis 
 
Melanin is a polyanionic polymer derived from the amino acid tyrosine mainly via 
enzymatic and spontaneous reactions (Prota 1980; Ings et al. 1984). There are two types 
of melanins; eumelanin and pheomelanin. They have different molecular structures and 
are different in color; eumelanin is brown or black and pheomelanin is yellow or red. 
Tyrosine is oxidized by the enzyme tyrosinase to dopaquinone, which is the final 
common precursor of the two melanin types (Figure 2). Eumelanins consist of 5,6-
dihydroxyindole (DHI) and 5,6-dihydroxyindole-2-carboxylic acid (DHICA) derived 
subunits, which are formed spontaneously from dopaquinone. Pheomelanins consist of 
sulfur containing benzothiazine derivatives that are formed when cysteine or other thiol 
compounds are present to react with the dopaquinone to form cysteinyldopa (Prota 
1980; Ito and Wakamatsu 2003). Although multiple enzymes are involved in melanin 
synthesis, only tyrosinase is essential for the process. 
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Figure 2. The biosynthesis of melanin from tyrosine or DOPA (modified from Ito et al. 
2011). 
 
After the formation of dopaquinone, melanogenesis can be divided into three 
subsequent stages (Figure 3) (Ito and Wakamatsu 2008). The first stage is the formation 
of cysteinyldopa in the presence of cysteine. The second stage is the oxidization of 
cysteinyldopa to pheomelanin. The last stage is the formation of eumelanin. The last 
step happens when the concentrations of cysteine and cysteinyldopa are sufficiently low 
for the first and second steps to stop. Thus the ratio of pheomelanin and eumelanin 
production depends on the activity of tyrosinase and the availability of tyrosine and 
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cysteine. In a low cysteine concentration, the first and second stages are insignificant, 
and the last stage leading to eumelanin production is predominant. 
 
 
Figure 3. Three stages of melanogenesis. Eumelanogenesis is favored when tyrosinase 
activity is high and cysteine levels are low (left). Pheomelanogenesis is favored when 
tyrosinase activity is low and cysteine levels are high. CD=cysteinyldopa, 
PM=pheomelanin, EM=eumelanin. (Ito and Wakamatsu 2008)  
 
Melanin is synthesized in melanosomes; lipid membrane covered intracellular 
organelles that contain melanogenic enzymes and cofactors (Kushimoto et al. 2001). 
Melanosome containing cells are called melanocytes. After the earliest stages of 
maturation, melanosomes have an organized, fibrillar matrix where the synthesized 
melanin will bind. Melanin is synthesized as long as there is active tyrosinase in the 
melanosome. When the melanosome is full, the tyrosinase activity ceases, ending the 
melanin synthesis. 
 
The pH of melanosomes affects the ratio of eumelanin and pheomelanin formation by 
affecting tyrosinase activity and the rate of reactions in the first and second stages 
(Figure 3) (Ancans et al. 2001; Ito and Wakamatsu 2008). At a neutral pH, 
eumelanogenesis is favored and at acidic pH more pheomelanin is formed. Tyrosinase is 
most active in near neutral pH and the activity ceases with decreasing pH. Low 
tyrosinase activity leads to low dopaquinone levels, which favors pheomelanogenesis. 
The cyclization of cysteinyldopa (stage two) leading to pheomelanin formation is faster 
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in a low pH and the cyclization of dopaquinone to cyclodopa (stage three) leading to 
eumelanin formation is slower. This also favors pheomelanogenesis. Higher tyrosinase 
activity in near neutral pH increases eumelanogenesis. 
 
The pH of most melanosomes is acidic (Bhatnagar et al. 1993; Puri et al. 2000; Ancans 
et al. 2001). Bhatnagar et al. (1993) determined the melanosomal pH of B16 murine 
melanoma to be between 3.0 and 4.6. Others have determined the pH of melanosomes 
in the skin to be acidic as well (Puri et al. 2000; Ancans et al. 2001). Fuller et al. (2001) 
however noticed a difference in the pH of melanosomes from Caucasian and black skin. 
While the pH of Caucasian skin melanosomes was acidic, the pH of black skin was 
more neutral. The pH of ocular melanosomes has not been studied, but it is expected to 
be acidic. The turnover of melanin and the activity of tyrosinase in ocular melanosomes 
are low, suggesting a low melanosomal pH (Hu et al. 2008). Detailed studies of the pH 
of ocular melanosomes are needed.  
 
2.2 Melanin in ocular tissues 
 
In the eye, melanin is found primarily in the uvea and retinal pigment epithelium (RPE), 
but the sclera also contains melanin (Figure 4) (Ings et al. 1984; Hu et al. 2008; Durairaj 
et al. 2012). The RPE continues on the surface of the uvea as ciliary and iris pigment 
epithelia (IPE). Other uveal melanocytes are located in the stromas of the iris and ciliary 
body and in the choroid. Melanocytes in ocular pigment epithelia (i.e. RPE, IPE and 
ciliary pigment epithelium) are of different embryonic origin than other ocular 
melanocytes. Melanocytes in these pigment epithelia are derived from the neural 
ectoderm (near the optic cup) whereas other ocular melanocytes are derived from the 
neural crest.  
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Figure 4. Location of melanin in the eye (red): retina, choroid, sclera, iris, and ciliary 
body. 
 
2.2.1 Retinal pigment epithelium 
 
The formation of melanosomes in the RPE takes place early during fetal development 
and melanin synthesis continues until approximately two years of age (Hu et al. 2008). 
It is not known whether there is any melanin turnover in mature human RPE cells but 
since aging causes the melanin content of these epithelial cells to decrease significantly, 
melanin turnover is either very slow or entirely absent (Schmidt and Peisch 1986; Hu et 
al. 2008). 
 
The RPE is densely pigmented and contains mainly eumelanin (Hu et al. 2008). The 
amount of melanin in the RPE does not vary significantly with race or iris color (Weiter 
et al. 1986; Wakamatsu et al. 2008). Melanin is distributed in the RPE so that there is a 
peak of melanin density at the macula, but around the macula the density is the lowest 
and again increases towards the equator (Weiter et al. 1986). The amount of melanin 
decreases with age with a largest decrease in peripheral (close to the equator) melanin. 
The average amount of melanin in the combined RPE-choroid is approximately 7.5 mg 
per eye (Table 1) (Menon et al. 1992). 
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In addition to eumelanin and pheomelanin, the molecular composition of melanosomes 
includes proteins and lipids. Azarian et al. (2006) identified 102 proteins in porcine RPE 
melanosomes. These are proteins that are involved for example in melanogenesis, 
organelle acidification, proteolytic enzymes, and transporters and channels. Ward and 
Simon (2007) analyzed the lipid composition of bovine ocular melanosomes. They 
found that there are significant differences between melanosomes in the RPE and uvea. 
The major component of uveal melanosomes is sphingomyelin while 
glycerophosphoethanolamine is the most abundant species in RPE melanosomes. The 
functional role of melanosomal lipids is however mostly undetermined.  
 
2.2.2 Uveal melanin 
 
As mentioned earlier, uveal melanocytes are divided into epithelial melanocytes and 
other uveal melanocytes. Uveal epithelial melanocytes (ciliary epithelium and IPE) are 
similar to the RPE and contain mostly eumelanin (Prota et al. 1998). Other uveal 
melanocytes can be further categorized in choroidal, iridial and ciliary melanocytes. 
According to Prota et al. (1998) and Wakamatsu et al. (2008) iridial melanocytes 
contain both pheomelanin and eumelanin and the amount and ratio of these melanin 
types in the iris determines the color of the eye. Eyes with dark colored irides have a 
larger amount of eumelanin in uveal melanocytes and a larger eumelanin/pheomelanin 
ratio than eyes with light colored irides. In light colored eyes the 
eumelanin/pheomelanin ratio is smaller but the amount of pheomelanin is similar. 
Wielgus and Sarna (2005) argued that a minimal fraction (a few percent) of iridial 
melanin is pheomelanin. They however used the iris as a whole (both iridial 
melanocytes and IPE). Since the IPE contains mostly eumelanin and is much more 
densely pigmented than iridial melanocytes, the contribution of iridial melanocytes is 
left minimal (Wakamatsu et al. 2008). Menon et al. (1992) found no significant 
difference in the amount of melanin in the iris of brown and blue eyes when the iris was 
again used as a whole. The average amount of melanin in the iris was 2.1 mg (Table 1).  
 
The color of the iris can be expected to affect the extent of melanin binding because of 
differences in the amount of melanin. Menon et al. (1992) found no difference in the 
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amount of timolol bound to iridial melanin from blue and brown eyes in vitro. However, 
indications of differences in binding have been obtained in vivo (Salminen et al. 1985). 
Salminen et al. studied the effect of timolol on the intraocular pressure in humans with 
blue or brown eyes. There was no reduction in intraocular pressure in the brown colored 
eyes but in blue colored eyes the reduction was significant. The main cause for this 
difference was concluded to be pigment binding in the iris. 
 
Choroidal melanin is also mainly eumelanin (Wakamatsu et al. 2008). Melanin density 
in the choroid is the highest at the macula and decreases towards the equator (Weiter et 
al. 1986). There is a statistically significant difference in the melanin content of the 
choroid Caucasian and black eyes with black eyes having more melanin than Caucasian 
eyes.  
 
Table 1. Total amounts of melanin and melanin types (eumelanin or pheomelanin) in 
ocular tissues. 
 
Tissue 
Amount of 
melanin/tissue (mg) Melanin type (Eu/Pheo) 
RPE 
7.5
1
  
mainly eumelanin
2 
Choroid mainly eumelanin
2 
Iris 
2.1
1 2-50 % pheomelanin*
2 
IPE mainly eumelanin
2 
*depends on the color of the eye 
1
(Menon et al. 1992), values for RPE + choroid and iris + IPE  
2
(Prota et al. 1998) 
 
 
2.2.3 Species variation 
 
There are some comparative studies on the species variation of the type of ocular 
melanin and the content of melanin in different parts of the eye. Liu et al. (2005) studied 
the type of melanin in the choroid, RPE and iris of mature and newborn bovine eyes. 
They found that all of these tissues contain mainly eumelanin with pheomelanin content 
being very low in the choroid and RPE (0.1-0.5 %) and moderate in the iris (< 2 %). 
Kadam et al. (2011) studied the melanin content of the sclera and choroid-RPE of albino 
and pigmented rabbits, pigs, cows, and brown Norway (BN) rats. Melanin content in the 
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sclera was rather low in all species. Melanin content in the choroid-RPE was in the 
order of BN rat > porcine ~ bovine > pigmented rabbit > albino rabbit. The melanin 
content of human choroid-RPE reported by Menon et al. is between that of the 
pigmented and albino rabbits (Menon et al. 1992; Kadam et al. 2011). Durairaj et al. 
(2012) studied the differences of melanin content in various ocular tissues in humans, 
minipigs (two strains), rabbits (two strains), dogs and monkeys. In the central choroid-
RPE all other species had significantly higher melanin contents than humans. In the 
peripheral choroid-RPE the case was the same except for the other minipig strain that 
had equal melanin content to humans.  
 
There are some studies that compare isolated ocular melanin from different species to 
synthetic melanin by analyzing particle size and surface area (Koeberle et al. 2003; 
Pitkänen et al. 2007). Pitkänen et al. found that the particle size of isolated bovine 
melanin and synthetic melanin in a buffered saline solution were similar after the 
solution was sonicated. Synthetic melanin tended to aggregate more vigorously during 
storage but aggregation happened also with bovine melanin. The specific surface area of 
bovine melanin was smaller than that of synthetic melanin. Koeberle et al. (2003) 
compared isolated bovine and Sepia melanin and synthetic melanin. They found that 
synthetic melanin had a smaller particle size than Sepia melanin. Bovine melanin had a 
wide size distribution with both smaller and much larger particles than synthetic and 
sepia melanin. 
 
2.3 Functions of ocular melanin 
 
All of the functions melanin may have are not entirely known. In the eye, the absorption 
of light is thought to be the most important function (Sarna et al. 1992; Hu et al. 2008). 
Melanin absorbs near infrared light, visible light, and ultraviolet (UV) radiation. In the 
iris it controls the visible and UV light entering the eye and protects the eye of their 
harmful effects. In the RPE melanin protects the neural retina from getting exposed to 
too much light, minimizing reflection and improving image quality. 
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Melanin acts as an antioxidant and protects the eye against free radicals. This may help 
protect against diseases such as uveal melanoma and age related macular degeneration 
(AMD) (Hu et al. 2008). Eumelanin is shown to be more antioxidative than 
pheomelanin although both melanin types act as antioxidants. There is a higher 
incidence of AMD in people with light-colored eyes; this is believed to be related to 
lower amounts of eumelanin in the uvea. Eumelanin, as being also the more 
photoprotective species, protects uveal melanocytes against malignant changes causing 
uveal melanoma. On the other hand, constant exposure of melanocytes to oxidizing 
agents (free radicals, light) in the aging eye may reduce the antioxidant effect of 
melanin and melanin may even act as a pro-oxidant (Sarna 1992; Hu et al. 2002).  
 
Melanin is known to bind many chemicals, protecting the eye from their harmful effect 
(Larsson 1993). Among these are free radical forming heavy metal ions like iron and 
copper and harmful organic compounds, for example drugs. By binding chemicals 
melanin can also act as reservoir. Depending on the nature of the chemical, this effect 
can be harmful, if it causes the chemical to accumulate to melanocytes. 
 
2.3 Binding of drugs to melanin 
 
Melanin binding of drugs is widely known (Potts 1964a; Ings et al. 1984; Larsson 
1993). The exact mechanism of binding, however, remains undetermined. As previously 
mentioned, melanin is a polyanionic compound. Electrostatic interactions are thought to 
be the main contributing mechanism of binding (Ings et al. 1984; Larsson and Tjälve 
1979; Lowrey et al. 1997). Other mechanisms include van der Waals forces and 
hydrophobic interactions. Lowrey et al. (1997) developed a TLSER (theoretical linear 
solvation energy relationship) model to convey the binding in relation to molecular 
descriptors of a set of drugs. The model suggested that the interaction was electrostatic 
in nature. Chloroquine seemed to be an exception in the model, hinting that electrostatic 
forces are not the main mechanism in its binding. Larsson and Tjälve (1979) as well as 
Stepien and Wilczok (1982) have also suggested that non-electrostatic interactions are 
important in chloroquine-melanin binding and that the binding of chloroquine may even 
be partly irreversible. Van der Waals forces were suggested to be the main contributing 
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interaction in the binding of chloroquine. Thus it is evident that different mechanisms 
contribute to drug-melanin binding depending on the nature of the drug. 
 
There is a relationship between the physicochemical properties of a drug and its binding 
to melanin (Ings 1984; Zane et al. 1990; Leblanc et al 1998). All basic and lipophilic 
drugs can be expected to bind to melanin (Leblanc et al. 1998). This is expected, since 
the melanin polymer is polyanionic. Ings (1984) found a good correlation between 
melanin binding and the pKa of benzodiazepines. Zane et al. (1990) found a good 
correlation between the acid/base status, pKa and octanol/water partitioning coefficient 
(logP) of a drug and its retention in ocular melanin. Others have confirmed these 
correlations (Kadam and Kompella 2010). 
 
By binding drugs, melanin can act as an intracellular drug reservoir. This can lower the 
free, i.e. effective, concentration of the drug inside the cell and thus affect drug 
response. Binding can also protect the cell from toxic effects of the drug by limiting the 
intracellular free drug concentration. Studies have shown that certain drugs have 
harmful effects in the eyes of albino rats but not in pigmented rats (Leblanc et al. 1998). 
Melanin can, however, also accumulate the drug in melanin containing tissues, like the 
eye, and expose the melanin containing cell to toxic effects of the drug. Although 
melanin binding may play a role in the toxicity of a drug to certain tissues, the binding 
itself does not indicate that a drug is toxic (Leblanc et al. 1998).  
 
Since the amount of eumelanin in ocular tissues is much larger than that of 
pheomelanin, eumelanin can be considered to be quantitatively more important in drug 
binding. It has been shown, however, that both melanin types bind drugs (Mårs and 
Larsson 1999). Mårs and Larsson determined pheomelanin binding of six compounds 
known to bind to eumelanin. The studies were performed with synthetic pheomelanin. 
All of these compounds bound to pheomelanin but mainly to a lesser extent. The 
binding to pheomelanin varied between 29-98 % of the binding to eumelanin (Table 2). 
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Table 2. Comparative results of pheomelanin and eumelanin binding. In vitro studies 
were performed with synthetic pheomelanin and bovine ocular eumelanin (Mårs and 
Larsson 1999). 
 
Compound Binding (%)   Binding ratio 
  Pheomelanin Eumelanin Pheo/Eu 
Acridine orange 98 100 0,98 
Clomipramine 23 80 0,29 
Chloroquine 27 92 0,29 
Chlorpromazine 36 86 0,42 
Nickel 47 88 0,53 
Paraquat 22 77 0,29 
7 ml of 2.5 µM solution of the compound was incubated with 5 mg of the melanin in question. 
 
 
 
3 METHODS FOR STUDYING MELANIN BINDING 
 
Ocular melanin binding has been studied with various methods including in vitro 
methods with isolated or synthetic melanin; ex vivo methods with isolated ocular tissues 
and in vivo methods with pigmented and albino animals (Potts et al. 1964a; Ings et al. 
1984; Menon et al. 1989). Binding studies concerning other than ocular melanin are 
similar to the methods used in ocular studies and in vitro studies with isolated or 
synthetic melanin are relatable to melanin binding in other tissues than the eye (Bathory 
et al. 1987; Larsson 1993; Karlsson et al. 2009). These methods concerning other 
tissues are not discussed here in detail. 
 
3.1 In vitro studies with melanin 
 
The simplest way to study melanin binding of drugs is with isolated or synthetic 
melanin. This method involves adding a compound solution to a melanin suspension, 
incubating and separating the insoluble melanin and bound drug from the solution (Potts 
1964a). These melanin binding studies have been done since Albert Potts introduced 
this simple method to study the binding in 1964. Potts first used isolated bovine uveal 
melanin and synthetic DOPA-melanin to study the interaction of chlorpromazine with 
melanin pigment (Potts 1964a). In the same number of the same journal he published 
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results of the recovery of chlorpromazine and chloroquine from isolated bovine 
choroidal melanin with an alkaline alcohol solution (Potts 1964b). Since then numerous 
binding studies have been performed with different compounds using melanin from 
different sources.  
 
3.1.1 Binding parameters of in vitro studies 
 
Most in vitro binding studies present a maximum binding capacity (Bmax, nmol/mg of 
melanin) and an equilibrium dissociation constant (Kd, µM) to depict the binding (Aula 
et al. 1988; Koeberle et al. 2003; Pitkänen et al. 2007; Pescina et al. 2012). Instead of 
equilibrium dissociation constant, equilibrium affinity constant is also used (Wilczok et 
al. 1990). This is the reciprocal of Kd. These parameters have been calculated either by 
fitting the results to a Langmuir binding isotherm or by Scatchard analysis. 
 
Melanin binding is treated as being analogous to the adsorption of a drug on a solid 
(Cheruvu et al. 2008). This means using type I binding isotherms, in which the binding 
reaches a plateau when a monolayer is formed. The Scatchard method compares the 
amount of bound ligand to the ratio of the amount bound and the free concentration of 
the ligand (Equation 1; Figure 5). It is a linear representation of the Langmuir binding 
isotherm (Equation 2). 
 
 
   
 
  
  
 
    
  
   (1)  
 
where B is the amount of bound ligand (nmol/mg of melanin),  Bmax is the maximum 
binding capacity (nmol/mg), [L] is the free ligand concentration (µM) and Kd is the 
equilibrium dissociation constant (µM). 
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Figure 5. Scatchard plot. Bmax = maximum binding capacity (nmol/mg), Kd = 
equilibrium dissociation constant, B = bound amount (nmol/mg), [L] = free ligand 
concentration (µM). 
 
Linear representations of binding equations are outdated, since more accurate nonlinear 
curve fitting programs have become available (Invitrogen 2006). A more common way 
to calculate binding parameters nowadays is nonlinear curve fitting to the Langmuir 
binding isotherm (Equation 2). This is a better method compared to the Scatchard 
method, since in the Scatchard method the axis values are not independent as the bound 
amount (B) is featured in both x and y axes (Invitrogen 2006). 
 
  
       
      
    (2) 
 
There are also other binding isotherms that could be used. Bridelli et al. (2006) 
compared the fit of different binding isotherms to binding results obtained with three 
drugs with different physicochemical properties. In addition to the Langmuir isotherm, 
the results were fit to the Freundlich (Equation 3), Temkin (Equation 4) and Dubinin-
Radushkevich isotherms (Equation 5). These isotherms are based on different 
assumptions; the Langmuir isotherm assumes that adsorption happens at homogenous 
sites as a formation of a monolayer on a surface, the Freundlich isotherm is used for 
heterogeneous sites; the Temkin isotherm considers the effects of indirect adsorbent-
adsorbate interactions on binding isotherms, and the Dubinin-Radushkevich isotherm 
expresses adsorption onto a heterogeneous surface. The studied drugs were gentamicin, 
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methotrexate, and chlorpromazine. Gentamicin was best fitted to the Freundlich 
isotherm, methotrexate to the Langmuir and Dubinin-Radushkevich isotherms, and 
chlorpromazine to the Langmuir and Temkin isotherms. Methotrexate and 
chlorpromazine fitted well to all the isotherms (R
2≥0.95) (Table 3). Gentamicin had a 
very poor fit to the Dubinin-Radushkevich isotherm, but somewhat good fits to the 
others (R
2≥0.93). Gentamicin is the most hydrophilic of the three drugs, methotrexate is 
somewhat hydrophilic, and chlorpromazine is lipophilic. Thus it can be concluded that 
the physicochemical properties affect the mechanism of interaction with melanin and 
could be considered in the analysis of the binding data. However, conclusions cannot be 
made of the suitability of a certain isotherm to a drug with certain physicochemical 
properties since the results for the different drugs compared were obtained with 
different types of melanin (synthetic, bovine and melanoma melanin), which can affect 
the results as well. 
 
Freundlich isotherm:            (3) 
Temkin isotherm:    
  
 
        (4) 
Dubinin-Radushkevich isotherm:         
      (5) 
 
where B is the bound amount (mol/g), Kf is a the Freundlich constant (l/g) estimating the 
adsorption capacity, L is the free concentration of the ligand at equilibrium (mol/l), R is 
the gas constant (8.314 J/mol/K), T is the temperature (K), b is the Temkin isotherm 
constant, A is the Temkin equilibrium constant (l/g), Bmax is the maximum binding 
capacity (mol/g), β is a constant related to sorption energy and ε is the Polanyi 
potential. 
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Table 3. Correlation values for binding results of gentamicin, methotrexate, and 
chlorpromazine fitted to four different type I binding isotherms (Bridelli et al. 2006). 
Drug Gentamicin Methotrexate Methotrexate Chlorpromazine 
Melanin type Synthetic B16 melanoma Synthetic Ocular (bovine) 
Correlation coefficients (R
2
)         
Langmuir 0,95 0,995 0,997 0,98 
Freundlich 0,98 0,95 0,95 0,94 
Temkin 0,93 0,98 0,99 0,98 
Dubinin-Radushkevich 0,66 0,99 0,997 0,96 
 
 
Other binding isotherms than the Langmuir isotherm are rarely if ever used in melanin 
binding studies. The results by Bridelli et al. (2006) suggest that there might not be a 
need to consider using other isotherms, since all drugs in the study fitted well to the 
Langmuir isotherm. The Langmuir isotherm is also the simplest considering the 
parameters it provides. In addition, gentamicin, that had the poorest fit to the Langmuir 
isotherm, is a very hydrophilic drug, which is rarely the case with new drugs. Therefore 
the Langmuir isotherm is the most rational isotherm choice. 
 
Bridelli et al. (2006) also studied the association kinetics of melanin binding. The 
results for the association of gentamicin were fitted to pseudo-first (Equation 6) and 
second-order kinetic equations, to an intraparticle diffusion model and to the Elovich 
equation (Equation 7). The best fits were achieved with the Elovich equation and first-
order equation. The results did not fit to the pseudo-second-order equation. The first-
order equation gives a parameter that is the most straightforward to interpret, since this 
model gives only one rate constant that is directly related to the differences in the 
amounts bound at different time points. This model would be the simplest to use in 
pharmacokinetic models of melanin binding. In a pseudo-first order reaction, the 
concentration of the other interacting species, in this case melanin, is assumed to stay 
constant (i.e. very high compared to the other species), thus this concentration is 
included in the rate constant according to Equation 8. 
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              (6) 
   
  
           (7) 
           (8) 
 
where Bt (mg/g) is the amount bound at time t (min), Be is the amount bound at 
equilibrium (mg/g), k1 is the pseudo-first-order association rate constant (min
-1
), a 
(mg/g/min) and b (g/mg) are Elovich equation constants, corresponding to the rate of 
sorption and the extent of surface coverage, respectively, k is the actual association rate 
constant (min
-1
M
-1
), and [M] is the concentration of binding sites on melanin (M). 
 
The Scatchard analysis, mentioned earlier, is used also for the evaluation of whether 
there are separate binding site classes for the binding ligand on melanin (Figure 6) 
(Aula et al. 1989; Invitrogen 2006; Pitkänen et al. 2007). A linear Scatchard plot 
indicates one binding site class. A concave-up Scatchard plot can indicate two binding 
site classes or negative cooperativity in binding. In melanin binding studies where 
Scatchard analysis has been performed, the concave-up curve has been taken as an 
indication of two binding site classes. The Scatchard plot can also be a concave-down 
curve, indicating positive cooperativity. This kind of binding has not been met with 
melanin. 
 
 
Figure 6. Scatchard plots. A linear plot indicates one binding site class (left), a concave-
up curve two binding site classes (middle), and a concave-down curve positive 
cooperativity. B is the bound amount of ligand, LF the free ligand concentration, Kd the 
equilibrium dissociation constant and RT the total amount of binding sites (the same as 
the maximum binding capacity, Bmax). (Invitrogen 2006) 
 
Association to melanin is known to be rather fast, happening within hours (Aula et al. 
1988; Pitkänen et al. 2007). There are only a few studies reporting values for 
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association rate constants (Aula et al. 1988; German et al. 1999). German et al. (1999) 
studied the association of five antimuscarinic drugs, including for example atropine, 
from Sepia melanin. They found the dissociation to be biphasic with significantly 
differing fast and slow phases. The association happened within 2 hours. They reported 
association rate constants of 287 x 10
6
 µM
-1
min
-1
 and 1.43 x 10
6
 µM
-1
min
-1
 for the fast 
and slow phase, respectively, for atropine. These values seem surprisingly large, since 
for example in the case of receptor binding, where association happens within 
10 minutes, the rate constants are smaller. Thus an error has most likely occurred in the 
calculation. Aula et al. (1988) studied the association of timolol to bovine ocular 
melanin and also got two association rate constants, 5.95 µM
-1
min
-1
 and          
0.492 µM
-1
min
-1
. The association happened within five hours. These values seem more 
reasonable. 
 
There is rather limited information in the literature about the dissociation of drugs from 
melanin. Aula et al. (1988; 1989) studied the dissociation of timolol and prostaglandin 
F2α from bovine ocular melanin. They found the dissociation to be linear with 
dissociation rate constants of 0.0051 min
-1
 and 0.025 min
-1
. German et al. (1999) also 
studied the dissociation of five antimuscarinic drugs. They found the dissociation to be 
monophasic, with a rate constant of 0.01 min
-1
 for atropine. The other drugs had smaller 
dissociation rate constants, the smallest being 0.003 min
-1
 for tropicamide. 
 
The dissociation rate from melanin can be considered a more important parameter than 
the association rate, as it reveals how long the drug would stay melanin bound and is 
released from melanin after dosage. In the few studies on this issue, dissociation has 
been a slower process than association, thus affecting the time course of melanin 
binding more significantly (Aula et al. 1988; German et al. 1999). 
 
3.1.2 Melanin sources for in vitro studies 
 
The most common sources for isolated melanin used in binding studies on ocular 
melanin are bovine and porcine eyes and Sepia officinalis (cuttlefish) (Potts 1964a; Ings 
1984; Koeberle et al. 2003; Buszman et al. 2008). In addition, synthetic melanin is also 
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used. Synthetic melanin is prepared from dihydroxyphenylalanine (DOPA) or tyrosine 
via oxidation by an oxidizing agent, e.g. hydrogen peroxide, or by tyrosinase (Potts 
1964a; Sigma-Aldrich 2014b). Synthetic and Sepia melanin are available also 
commercially (Sigma-Aldrich 2014b). Synthetic melanin differs structurally from 
natural (isolated) melanin (Nosfinger et al. 2000). Nosfinger et al. studied the structures 
of synthetic and Sepia melanin (eumelanin) by scanning electron microscopy. They 
came to the conclusion that natural eumelanin has a larger size-to-volume ratio than 
synthetic melanin. This means there are more reactive sites on natural melanin per 
weight unit of melanin, which can affect the protective properties of melanin as well as 
the capacity of compound binding. One of the reasons they proposed for this difference 
was the different molecular structures of these melanin types. As eumelanin is 
constituted of DHI and DHICA-derived units, synthetic melanin is mainly formed from 
DHI-derived units. 
 
Melanin binding has been studied in many reports and several studies have included the 
same drugs in their test repertoire. There are however only a few comparative studies 
with melanin from different sources (Potts 1964a; Aula et al. 1989; Koeberle et al. 
2003; Pitkänen et al. 2007; Cheruvu et al. 2008). These studies have mostly compared 
an isolated natural melanin to synthetic melanin; only Koeberle et al. (2003) compared 
two natural melanins, Sepia and bovine ocular melanin. In most of the studies (except 
for Potts (1964a) and Cheruvu et al. (2008)), there were differences in the results 
obtained with different melanins. Koeberle et al. (2003) studied only the binding of 
memantine and found that Sepia and synthetic melanins had a maximum binding 
capacity of 68 and 54 % of that of bovine ocular melanin, respectively, when studied in 
phosphate buffered saline (PBS) (Table 4). Affinities of binding were similar with Sepia 
and synthetic melanin but bovine ocular melanin only had an affinity of half of the 
values of the other melanins. They also found differences in the binding parameters 
when the interaction was studied in deionized water instead of saline. One of the 
reasons for this difference is metal ions in the saline solution binding to melanin and 
decreasing the ability of other compounds to bind (Wrzesniok et al. 2012).  In deionized 
water, Sepia melanin had the highest binding capacity and synthetic melanin the 
smallest, with affinities being similar with all melanins (Koeberle et al. 2003). This is an 
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indication of differing structures of these melanins and differences in the results caused 
by the study environment. Pitkänen et al. (2007) compared bovine choroid-RPE melanin 
to synthetic melanin with two beta-blockers, betaxolol and metoprolol. They found that 
synthetic melanin bound significantly more drug per mass unit of melanin. When the 
results were normalized to the surface area of melanin the differences were much 
smaller. Cheruvu et al. (2008) studied the binding of celecoxib to synthetic and Sepia 
melanin but found no significant difference in binding. They did not perform a surface 
area measurement, thus the relation of binding to surface area was left unclear.  
 
Table 4. Results of melanin binding studies comparing melanin from different sources. 
 
Drug Parameters Melanin source     
    Sepia Synthetic Bovine ocular 
Koeberle et al. (2003) 
    Memantine Bmax (nmol/mg) 140 111 207 
(PBS) Kd (µM) 452 442 804 
Memantine Bmax (nmol/mg) 466 272 364 
(deionized water) Kd (µM) 435 488 351 
Pitkänen et al. (2007) 
    Betaxolol Bmax (nmol/mg) - 0.152 / 36.3
1
 0.013 / 27.5 
 
Kd (µM) - 0.642 / 97.6 0.026 / 249 
Metoprolol Bmax (nmol/mg) - 0.166 / 40.7 0.096 / 26.9 
  Kd (µM) - 0.915 /172 0.832 / 495 
Aula et al. (1989) 
    Prostaglandin F2α Bmax (nmol/mg) - 0.0034 / - 
2 
0.0025 / - 
  Kd (µM) - 0.0050 / 0.19 0.0037 / 1.99 
1
Pitkänen et al. (2007) reported values for two binding site classes. 
2
Aula et al. (1989) reported a maximum binding capacity (Bmax) only for the high affinity site. 
 
The largest differences in binding with melanin from different sources have been 
obtained with methotrexate. There are studies where methotrexate bound to melanin at 
neutral or near neutral pH and studies where no binding happened (Tsuchiya et al. 1987; 
Hayasaka et al. 1988; Wilczok et al. 1990). Wilczok et al. (1990) studied the interaction 
with synthetic melanin and melanin from mouse B16 melanoma at pH 7.0. They found 
noticeable binding to both melanin types. Tsuchiya et al. (1987) studied the interaction 
with bovine ocular acid-insoluble melanin at pH values of 4.8, 7.4 and 8.0. 
Methotrexate did not bind at the higher pH values but at pH 4.8 melanin binding was 
seen. Hayasaka et al. (1988) obtained similar results as Tsuchiya et al. (1987) by 
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studying methotrexate binding to synthetic melanin at pH 4.8 and 7.0. The difference 
caused by the change in pH could be expected since methotrexate is a dicarboxylic acid 
with pKa values of 4.1 and 3.4. At the lowest pH, part of methotrexate is in the neutral 
form that is expected to bind better to melanin than the negatively charged form of 
methotrexate. This is explained by the polyanionic nature of melanin. The differences in 
binding at the near neutral pH are more curious. A possible explanation for these 
differences is the sources of melanin used, although deviant results were also obtained 
in the two studies done with synthetic melanin. There were no significant differences in 
other study conditions. Comparative studies should be performed to investigate the 
cause of this kind of a difference. 
  
Since studies have shown that there are differences in binding between synthetic and 
isolated melanin and even isolated natural melanin from different sources, the 
comparison of results from different studies and with different melanin sources should 
be done carefully. In most binding studies a surface area measurement of melanin has 
not been performed, which makes direct comparison difficult. Surface area is an 
important factor to consider since it directly affects the binding sites available for the 
binding ligand. If the results are needed only to see if a drug binds to melanin, the 
source of melanin does not seem to affect the conclusion. When more accurate results 
are required, the effect of melanin source on the results becomes more significant. More 
information is needed on the relation of binding and surface area and also the 
comparison of results from different binding studies. 
 
3.1.3 Affinity chromatography 
 
Synthetic melanin has also been used in melanin binding studies done with high 
performance liquid chromatography (HPLC) (Ibrahim and Aubry 1995; Knörle et al. 
1998). Synthetic L-DOPA melanin has been covalently linked to an aminopropyl silica 
(APS) stationary phase or formed in situ with the APS (Ibrahim and Aubry 1995). 
Ibrahim and Aubry (1995) studied the retention of five phenothiazines and determined 
binding parameters (maximum binding capacity and affinity) for two of those. When 
compared to literature results obtained with synthetic and bovine ocular melanin, the 
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results of the maximum binding capacity were similar, but the affinity to the stationary 
phase melanin was significantly lower. They concluded possible reasons for the 
difference to be the immobility of melanin and the different type of melanin used.   
Despite the differences, the use of this HPLC method could provide a simple and rapid 
method for studying melanin binding. Aubry (2002) later reviewed the advantages and 
disadvantages of this method, concluding it to be a useful tool to obtain comparative 
results with a set of compounds studied by this method. More information is needed 
however of the relation of these results to the binding study results obtained with the 
more common in vitro method addressed earlier. 
 
The investigations of melanin binding of drugs in vitro in early drug discovery would 
greatly benefit of methods suitable for high throughput screening. In addition to the 
affinity chromatographic method with HPLC, a magnetic bead method has been 
introduced (Marszall et al. 2011). In this method synthetic melanin was immobilized 
covalently to the surface of magnetic iron beads with a diameter of 1 µm. After the 
incubation of these melanin coated beads with the study compounds (phenothiazines), 
the supernatant with the free compound was removed with a magnetic separator for 
analysis. The melanin-covered beads were then washed by a special method and reused. 
The authors concluded this method to be suitable for high throughput screening and 
they were able to create a quantitative structure-property relationship (QSPR) model of 
calculated molecular descriptors related to the binding efficiency to the melanin coated 
beads. They suggested this to be a useful method to evaluate the affinity of drug 
candidates to melanin in early drug discovery. The created model is described more 
accurately later (see 4. Prediction of melanin binding). 
 
3.2 In vitro studies with melanosomes  
 
In addition to in vitro binding studies with melanin, binding has been studied with 
isolated melanosomes (Abrahamsson et al. 1988; Debing et al. 1988; Wilczok et al. 
1990). Debing et al. (1988) studied the binding of 15 drugs, including for example 
chloroquine, chlorpromazine, norepinephrine and nicotine, to bovine ocular 
melanosomes. All compounds bound and the binding curves seemed similar in shape 
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with melanin binding studies. No quantitative comparison to melanin binding of these 
drugs was done. Wilczok et al. (1990) studied the binding of methotrexate to 
melanosomes and melanin isolated from mouse B16 melanoma. Methotrexate bound to 
both melanosomes and melanin and no significant difference was found between the 
bound amounts when the amount bound to melanosomes was normalized to the melanin 
content inside the melanosomes. Abrahamsson (1988) studied the binding of beta-
blockers timolol and H216/44 to bovine ocular melanosomes. They compared the 
results to chlorpromazine, a high binding drug. Chlorpromazine had the highest binding, 
as expected, but both beta-blockers also bound. The maximum binding capacities of the 
beta-blockers were between 10-20 nmol/mg of melanosomes. The results were not 
compared to melanin binding results and the amount of melanin in the melanosomes 
was not analyzed. Thus it is difficult to draw conclusions on the correlation of these two 
study methods. The binding curves however were similar in shape as in melanin binding 
studies.  
 
The isolation methods of melanosomes have been similar to melanin isolation with a 
sucrose gradient, but no protease has been used (Abrahamsson 1988; Debing et al. 
1988; Wilczok et al. 1990; Pitkänen et al. 2007). Ocular tissues (choroid, iris, ciliary 
body and RPE) have been homogenized and then centrifuged with a sucrose gradient. 
This has been a common method for the isolation of melanin granules or melanosomes 
and separates the melanosomes from other cellular components, including mitochondria 
(Menon and Haberman 1974; Liu et al. 2005). In melanosome studies, the isolated 
product has been called either melanin granules or melanosomes. In the studies in which 
protease digestion has been used, the product has been called melanin granules or 
melanin. The authors have not commented more thoroughly on the composition of the 
product. The separation between melanosomes and melanin can thus be difficult. 
Pitkänen et al. (2007) got similarly shaped granules with protease digestion and 
subsequent sucrose gradient centrifugation as Liu et al. (2005) without protease 
digestion (Figure 7). The isolated melanosomes were not characterized in any of the 
binding studies with melanosomes (Abrahamsson et al. 1988; Debing et al. 1988; 
Wilczok et al. 1990), thus the quality of the melanosomes and whether they were intact 
remains undetermined.  
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Figure 7. Scanning electron micrographs of bovine ocular RPE melanosomes isolated 
without protease digestion (left) and bovine RPE melanin granules isolated using 
protease digestion (right). (Liu et al. 2005; Pitkänen et al. 2007) 
  
Since melanin is inside melanosomes in the cells, it would be beneficial to study the 
interaction with melanosomes instead of pure melanin. This resembles the in vivo 
situation since the lipid membrane covering the melanosomes affects the ability of 
drugs to reach the melanin (Larsson 1993). Although a compound may bind to melanin, 
it might not be able to reach the melanin inside the cells in vivo. Since no specific 
separation of the isolation methods of melanin and melanosomes has been made, the 
“melanin” in melanin binding studies may be very similar to those studies done with 
melanosomes. Protease digestion would be expected to deproteinize the granules, thus 
there may be a differences in the protein composition of the differently isolated 
granules. However, Larsson and Tjälve (1979) have shown that protein moieties do not 
affect the binding. Therefore the binding may be very similar in these differently 
isolated melanin granules. A comparative study would be needed on this matter to better 
evaluate the effect of isolation methods. 
 
3.3 Ex vivo studies 
 
Ocular melanin binding has also been studied ex vivo with enucleated eyes, layers of 
ocular tissue or tissue homogenates. A common ex vivo experiment is a permeation 
study across pigment containing cell layers, like sclera-choroid-Bruch’s membrane, 
isolated from animal eyes (Kadam et al. 2011; Pescina et al. 2012; Du et al. 2013). 
Kadam et al. (2011) studied the permeation of eight beta-blockers across the sclera, 
sclera-choroid-RPE and choroid-RPE of albino and pigmented rabbits, pigs and human. 
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Pescina et al. (2012) studied the permeation of four drugs across pigmented and non-
pigmented porcine sclera-choroid-Bruch’s membrane. Light blue porcine eyes were 
used as the non-pigmented control, since in these eyes melanin is only present in the 
RPE. Du et al. (2013) studied the permeation of triamcinolone acetonide across sclera-
choroid-Bruch’s membrane of albino and pigmented rabbits. The drawback of the 
studies by Pescina et al. and Du et al. is the RPE layer being left out of the tissue 
sample. Since the highest level of melanin in ocular tissues is in the RPE, the study does 
not take into account the entire barrier in permeation from the sclera border to the 
vitreous. However, a good estimate of the effect of melanin on the pharmacokinetics 
can be made, since the pigmented RPE of the light blue eyes does not interfere with the 
results. This kind of comparative results could be beneficial for a pharmacokinetic 
compartmental model, since they take into account the differences in the lag time in 
permeability caused by melanin binding.  
 
Kadam et al. (2011) also studied transscleral transport of eight beta-blockers to the 
vitreous by measuring the drug levels in different parts of the eye (sclera, choroid-RPE, 
retina, vitreous) after subconjunctival injection to a euthanized rat and subsequent 
enucleation of the eye after 6 hours (Kadam et al. 2011). Only pigmented rats were used 
for this study. Since there was no albino control, an accurate estimate of the effect of 
pigment could not be made. These results were however used for the assessment of the 
goodness of correlation of rabbit, porcine and human tissue layer models mentioned 
earlier. When studying pigment binding, a permeation study would be more rational to 
perform, since it is not as laborious as a whole tissue ex vivo study and the results are 
comparable. 
 
Menon et al. (1989) studied the melanin binding of timolol with excised and chopped 
ocular tissues; the iris and ciliary body as pigmented tissues and lens and cornea as non-
pigmented controls. The studies were done in a similar manner as in vitro binding 
studies, by letting the chopped tissue interact with timolol in solution. No significant 
difference was found between the pigmented and non-pigmented tissues when 
normalized to the wet weight of the tissue. This kind of a study gives a good idea of the 
binding to different parts of the eye but does not give reasonable estimates of the effect 
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of pigment binding since a negative non-pigmented version of the same tissue is not 
used. 
 
3.4 In vivo studies 
 
In addition to the methods mentioned earlier, melanin binding can be studied in vivo 
with autoradiography or other imaging methods like positron emission tomography 
(PET) or single photon emission computed tomography (SPECT) by giving an animal 
or human a radiolabeled dose of the drug in question. In fact, quantitative 
autoradiography in rats is often the first indication of melanin binding in drug discovery 
since binding is not routinely tested with other methods (Solon et al. 2002). 
Comparative studies can be done with albino and pigmented animals. 
 
There are numerous studies done with whole-body autoradiography (WBA) comparing 
albino and pigmented mice or rats (Lyden et al. 1982; Larsson et al. 1988; Bathory et al. 
1990). A common study design has been to give a single dose of a drug to the animal, 
then euthanize the animal after a certain time and measure the radioactivity. The desired 
tissue (e.g. the eye) can also be excised for the measurement. Study time frames have 
differed from a few hours to three months (Lyden et al. 1982; Bathory et al. 1990). In 
some studies, an in vitro melanin binding study has been performed as well. These 
kinds of studies give a good idea of the real situation in vivo and can help evaluate the 
relationship between melanin binding and tissue accumulation. However, no numerical 
relationships have been drawn in any studies to compare the in vivo situation to the in 
vitro melanin binding. Other imaging methods, PET and SPECT, have mainly been 
used so far for the diagnosis of melanoma by melanin binding indicators (Goto 2004; 
Kato et al. 2006). 
 
In addition to imaging methods, pigment binding has been studied in vivo by 
determining drug concentrations of excised tissues (Sauer and Anderson 1994; Cheruvu 
et al. 2008). The animal is dosed while alive. After a suitable time, the animal is 
euthanized and the desired tissue is excised, homogenized and analyzed with a suitable 
method (e.g. with HPLC).  The results obtained of these studies are similar to WBA, 
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except more accurate concentrations in the tissues and tissue fractions are obtained. 
Since there is no need for radioactive tracers, this method is simpler compared to 
imaging methods. 
 
Another way to study pigment binding in vivo, and more closely the effect of binding on 
the effect of a drug, is to study the differences in drug response of pigmented and albino 
animals. A common way to study drug response in ocular tissues has been to study 
intraocular pressure after the dosing of pressure decreasing drugs (antiglaucomatics) 
(Shibata et al. 1988; Nagata et al. 1993). These studies can also be done in humans 
comparing eyes with brown and blue irides (Salminen et al. 1985). Also miosis and 
mydriasis have been studied (Salazar et al. 1976; Urtti et al. 1984). While being a 
valuable tool in the evaluation of differences in drug response caused by pigment 
binding, these studies lack the possibility of providing accurate data of the quantity of 
drug bound to melanin in vivo.  
 
3.5 Cell models of melanin binding 
 
The results from in vitro binding studies are depicting only the interaction between 
melanin or melanosome and the drug, and do not take into account other processes 
happening in vivo. Studying the interaction with cells could therefore be beneficial. This 
would take into account some cellular factors, including melanin being inside cells and 
in the cells inside melanosomes, covered by lipid membranes that restrict access to 
melanin. 
 
Hornof et al. (2005) reviewed current cell models for ocular barriers, and from this 
review it is obvious that many cell culture models of the RPE do not take into account 
the effect of melanin. No literature could be found on melanin binding itself being 
studied with cells but a number of cell models of the RPE have been created. These 
cultures have been characterized by their morphology, bioelectric parameters 
(transepithelial electrical resistance), permeability, and expression of certain proteins. 
When evaluating melanin binding drugs with these cell models, it would be important to 
include the characterization of melanin content of the cells. 
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When studying melanin binding in vitro with cells, the cells should naturally be 
pigmented. Primary RPE cells contain melanin until at least the fourth passage and can 
be used in these studies (Dorey et al. 1990; Hornof et al. 2005). The use of primary cells 
however is laborious, since the isolation procedure is time consuming. Immortalized 
human RPE cells have been shown to become melanized (i.e. synthesize melanin) when 
kept in confluence for four weeks in serum free conditions or more than eight weeks in 
serum containing medium (Rambhatla et al. 2002). The use of these cells is however 
hindered by the long culture duration. There are also reported methods for increasing 
the melanin content of RPE cells in culture, such as feeding the RPE cultures melanin 
granules (Boulton and Marshall 1985; Basu et al. 1989). Boulton and Marshall (1985) 
fed isolated melanin granules to human RPE cells by incubating the cells in growth 
medium suspended with melanin granules. The granules were taken up by the cells and 
the cells remained melanized at least for seven days. The authors concluded this method 
to be a possibility for cell models of RPE that do not contain melanin. Basu et al. (1989) 
used a similar method successfully, reported in their published abstract. Kadam et al. 
(2012) developed an MDCK cell line model for the RPE with tunable melanin 
expression. MDCK cells were transfected by retroviral infection with genes of human 
tyrosinase and p-protein, a protein shown to play a role in the correct processing and 
localization of tyrosinase. These cells were compared with MDCK cells without 
melanin by doing uptake studies with chloroquine, a drug with very high affinity to 
melanin, and salicylic acid, a low affinity drug. The cell uptake of chloroquine was 2.3-
fold higher in pigmented MDCK cells than in non-pigmented cells. No difference was 
found with salicylic acid. Thus the melanin binding was shown to affect the uptake 
considerably. This kind of cells could be used in uptake studies of melanin binding and 
could help solve the problem of the need for primary or other time consuming cultures. 
 
To be able to use cell binding studies in pharmacokinetic modeling of melanin binding, 
the amount of melanin inside the cells should be measured. The melanin content of 
cultured primary RPE cells decreases over time (Dorey et al. 1990). Differences in 
melanin content will also occur when melanin granules are fed to the cells. Thus it is 
important to quantify the amount of melanin to be able to normalize the results to the 
amount of melanin. There are reported methods for the analysis of melanin content, the 
30 
 
most used being absorbance measurement of intact or lysed cells (Donatien and Orlow 
1995; Rambhatla et al. 2002; Kadam et al. 2012). These methods are not discussed here.  
 
 
4 PREDICTION OF MELANIN BINDING 
 
As mentioned earlier, melanin binding can be related to the physicochemical properties 
of the drug. Some quantitative structure property relationship (QSPR) models or similar 
quantitative models have been constructed (Raghavan et al. 1990; Radwanska et al. 
1995; Lowrey et al. 1997). These models are however not very comprehensive, since 
the sets of drugs used for model construction have been small and somewhat 
homologous. 
 
All basic and lipophilic drugs can be expected to bind to melanin, since these drugs 
have the potential to bind to the polyanionic melanin as well as cross the lipid 
membranes needed to access melanin inside cells. Zane et al. (1990) compared the 
physicochemical properties of 27 drug candidates to the distribution into the melanin-
containing uveal tract of the rat eye determined by whole body autoradiography. The 
physicochemical properties included were molecular weight (between 223 and 489), 
pKa, degree of ionization, logP, drug-melanin binding energy and acid/base status. 
Distribution was measured at 5 minutes and 96 hours after dosing. At 5 minutes, the 
primary factors affecting the distribution to the uveal tract were, in decreasing order of 
effect, acid/base status, pKa, binding energy, and logP. The retention (96 hour time 
point) in the uveal tract correlated best with the volume of distribution, logP, pKa and 
binding energy. The correlation predicted with these parameters was better in the 
distribution phase (5 min) than in the retention phase, the values of R
2
 being 0.961 and 
0.577, respectively. The authors concluded the most notable factor contributing to the 
poorer correlation at 96 hours to be metabolism. WBA does not differentiate between 
the drug and the metabolite. No quantitative model was created based on the 
physicochemical parameters.  
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The same group calculated drug-melanin binding energies using molecular modeling 
(Raghavan et al. 1990). They used a 5,6-dioxoindole (a monomer of melanin) as a 
tetramer as the model for melanin. Binding energies obtained by modeling were then 
compared with in vitro results. The correlation was good, with an R
2
 value of 0.811. 
They concluded that this method can be considered a significant predictor of melanin 
binding in vitro. 
 
The TLSER model (Equation 9) developed by Lowrey et al. (1997) of the equilibrium 
constant (K) of melanin binding was comprised of four prescriptors, “covalent” 
hydrogen bond basicity, εB “covalent” hydrogen bond acidity, εA, and electrostatic 
hydrogen bond basicity, q-. Other descriptors considered for the model but excluded for 
poor fits, were molecular volume, polarizability index, and electrostatic hydrogen bond 
acidity, q+. The R
2
 value for the equation was 0.77. 16 compounds were used for the 
model. 
 
                               (9) 
 
Radwanska et al. (1995) derived a quantitative structure retention relationship (QSRR) 
model by analyzing the retention of 15 phenothiazines with HPLC reported by Lowrey 
et al. (1997) and Markuszewski and Kaliszan (2002). They correlated an HPLC capacity 
factor to drug hydrophobicity determined on an immobilized artificial membrane 
column and the energy of lowest unoccupied molecular orbital determined by molecular 
modeling. Lowrey et al. (1997) transformed this QSRR to a TLSER model by 
substituting the parameters with surface area accessible to water and εA. Both of these 
models can be used to depict the mechanisms involved in binding, as well as to predict 
the binding of other similar drugs.  
 
As mentioned earlier, Marszall et al. (2011) introduced a magnetic bead method for the 
studying of melanin binding of drugs and created a QSPR model of the relationship of 
binding efficiency to melanin and calculated theoretically structural descriptors. These 
descriptors were calculated from the molecular formula of these compounds and have 
no definite physical meaning. This model was constructed with 17 similar compounds, 
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most of which were antipsychotics. It was concluded to describe well the binding 
efficiency of these compounds to melanin but also the potential of these compounds to 
cause extrapyramidal syndrome, a condition caused by antipsychotics that has been 
related to melanin binding in the central nervous system. Thus this model can be used in 
early drug discovery of this group of drugs. Although other possibilities, e.g. the 
evaluation of ocular toxicity, were mentioned for this model, the weakness of the model 
is the small number and similarity of the compounds used. 
 
Predictive models of melanin binding would be beneficial in drug discovery, helping to 
get an idea of whether melanin binding should be considered, possibly as a 
disadvantage or even an advantage e.g. in the form of a drug reservoir. Building a 
QSPR model of melanin binding would constitute a simple method in evaluating 
melanin binding already in early drug discovery. The weakness of the models built so 
far is the limited amount of compounds used. Much more extensive data should be used 
to be able to construct a comprehensive model. Also, pharmacokinetic modeling of 
melanin binding and its effect on the pharmacokinetics of drugs has never been done. It 
would be beneficial to include melanin binding to pharmacokinetic models of drug 
delivery to be able to evaluate the in vivo situation already in early drug discovery.  
 
 
5 AIMS OF THE STUDY 
 
The aims of the experimental part of the study were to evaluate the effect of melanin 
binding on cellular and ocular pharmacokinetics in the posterior part of the eye, more 
closely in the retinal pigment epithelium (RPE), and to construct a cellular level 
pharmacokinetic compartmental model of the binding. These aims were accomplished 
by:  
1. Investigating the melanin binding of a set of compounds in vitro with 
porcine ocular melanin and obtaining parameters depicting the amount and 
kinetics of melanin binding 
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2. Investigating the cellular pharmacokinetics of this set of compounds with 
porcine RPE (pRPE) cells and obtain parameters of cellular 
pharmacokinetics. 
3. Evaluating the effect of RPE efflux transporters (MRP1, MRP4 and MRP5) 
in the cell studies with a general efflux inhibitor probenecid 
4. Constructing a pharmacokinetic model of melanin binding and simulating it 
with the binding parameters obtained from in vitro studies 
5. Combining the binding model to a cell model and modeling the effect the 
binding has on cellular pharmacokinetics. 
 
 
6 MATERIALS AND METHODS 
 
6.1 Materials 
 
Nadolol and chloroquine diphosphate salt were obtained from Sigma-Aldrich (St. Louis, 
MO, USA). Timolol, carboxydichlorofluorescein (CDCF), methotrexate, 
dexamethasone and probenecid were all provided by The University of Helsinki. 
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich) was used as a solvent for the highest 
concentrations of stock solutions, which were then diluted with phosphate buffered 
saline (PBS) (pH 7.4, without CaCl2 and MgCl2) (Gibco, Invitrogen, NY, USA) or 
citrate buffer (pH 5) (APPENDIX 1). 
 
Cells were cultured in Dulbecco’s modified eagle medium (D-MEM) 31885 (Gibco, 
Invitrogen, NY, USA) supplemented with 10 % fetal bovine serum (FBS), 50 U/ml 
penicillin and 50 U/ml streptomycin. Cells were detached with 0.25 % trypsin-EDTA 
(Gibco) and washed with DPBS (with or without CaCl2 and MgCl2). 
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6.2 In vitro binding studies with melanin 
 
6.2.1  Isolation of melanin granules 
 
The melanin used in the binding studies was isolated from the RPE and choroid of 
porcine eyes. Fresh porcine eyes were obtained from a slaughter house (HK Ruokatalo, 
Forssa) and kept on ice during the transport. Extraocular material was cleaned from the 
eyes with scissors, the eyes were dipped in ethanol and then in PBS before the eyes 
were cut (first batch 51 eyes, second batch 26 eyes). The eyes were cut 
circumferentially behind the limbus and the anterior part of the eye with the vitreous 
was gently removed. The remaining eye cup was turned inside out. The outermost cell 
layer (neural retina) was gently removed uncovering the RPE and the choroid. The 
RPE-choroid was separated from the sclera, placed in PBS (pH 7.4) and stored at           
-20 ºC until melanin isolation. 
 
Melanin isolation from the RPE-choroids was modified from Pitkänen et al. (2007) and 
Pescina et al. (2012).  Subtilisin protease type VIII from Bacillus licheniformis (Sigma-
Aldrich, St. Louis, MO, USA) was added to the RPE-choroids in PBS, with the amount 
of the protease being at least 30 mg/25 eyes. The suspension was incubated at 56 ºC for 
one hour with manual stirring every 10 minutes and then heated to 95 ºC for 15 minutes 
to inactivate the protease. The suspension was centrifuged at 37 000 g for 15 minutes 
and the supernatant was discarded. The pellet was washed with PBS and centrifuged as 
above. The suspension was vacuum filtered on a Büchner funnel through filter paper. 
The filtrate was centrifuged at 37 000 g for 15 minutes and the precipitate was mixed 
with Milli-Q water and lyophilized overnight.  
 
6.2.2 Characterization of melanin granules 
 
Particle size of the melanin granules was measured with Zetasizer Nano ZS (Malvern 
Instruments, Worcestershire, UK). Larger aggregates were evaluated with a light 
microscope (Leica DM IL LED inverted microscope, Leica microsystems, Wetzlar, 
Germany) and images taken with Leica EC3 camera. Particle size measurements were 
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done in PBS at pH 7.4. Samples were prepared as in the binding study (see 6.2.3 
Binding study) and incubated in the same conditions for 0, 3, 5 or 20 hours. Since some 
particles were too large for measurement with the Zetasizer, all samples were filtrated 
with a 5 µm pore size Ultrafree-MC centrifugal filter (Millipore, Billerica, MA, USA). 
After filtration, the samples were diluted 1:10 to a 0.1 mg/ml melanin concentration. 
 
Zeta potential of the melanin granules was measured with the Zetasizer Nano ZS. Since 
there is an expected difference in zeta potential at different pH values, measurements 
were done in both experimental pH environments, pH 5 (in citrate buffer) and pH 7.4 
(in PBS). Both batches of isolated melanin were measured. 1 mg/ml melanin 
suspensions were made in both citrate buffer and PBS to mimic the experimental 
conditions of the binding studies. The suspensions were warmed to 37 ºC, sonicated for 
15 minutes, and diluted to a 0.2 mg/ml concentration for the measurement. 
 
6.2.3 Binding study 
 
Melanin binding studies were performed with six compounds; nadolol, timolol, 
chloroquine, carboxydichlorofluorescein (CDCF), methotrexate and dexamethasone. 
Stock solutions were made in DMSO (nadolol, timolol, CDCF, dexamethasone), Milli-
Q water (chloroquine) or 0.1 M sodium hydroxide (methotrexate). In the final solutions 
used in the binding experiments, DMSO concentration did not exceed 2 %. 
 
Melanin binding was studied with all the compounds at pH 7.4 and in addition at pH 5 
with methotrexate and CDCF. Methotrexate and CDCF are acidic compounds, the pKa 
values for methotrexate are 4.1 and 3.4 (a dicarboxylic acid) and for CDCF 5.1 (Table 
5). The other compounds are basic except for dexamethasone which is a very weak acid 
(pKa 11.4). Experiments at pH 7.4 were done in PBS and at pH 5 in citric acid buffer.  
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Table 5. Physicochemical properties and transporter interaction of the compounds 
studied. 
 
Compound logP logD (7.4) pKa Acid/base Efflux substrate 
Timolol 1.8
1 
0.34
1 
8.9
1 
base P-gp 
Nadolol 0.93
1
 -0.82
1 
9.2
1 
base no 
Chloroquine 3.7
2 
1.9
3 
8.1 and 10.4
2
 base MRP1
6
, P-gp 
Methotrexate - 0.45
3
 -4.9
3 
4.1 and 3.4
4
 acid MRP1-4, -8, BCRP, P-gp etc. 
CDCF 2.6
3 
-0.50
3 
5.1
5
 acid MRP5
7
 
Dexamethasone 1.9
2 
1.9
3 
11.4
4
 acid P-gp 
1
(Kadam and Kompella 2010)   
5
(Sigma-Aldrich 2014a) 
2
(Verbeeck et al. 2005)   
6
(Vezmar and Georges 1998)  
3
values predicted with ACD/Labs (Chemspider 2014) 
7
(Mannermaa et al. 2009) 
4
values predicted with ChemAxon (Chemspider 2014)   
If not otherwise indicated, efflux substrate information from TP-Search: Transporter Database (2014). 
 
Four types of binding studies were performed; kinetic studies to determine how long it 
takes for the binding to reach equilibrium; equilibrium studies to determine the 
maximum binding capacity (Bmax) and equilibrium dissociation constant (Kd); 
dissociation study to determine the rate constant for dissociation from melanin (koff), and 
association study to compare the calculated value of the association rate constant (kon) to 
the measured value (Table 6). 
 
Melanin suspension and test compound solutions were prepared right before every 
experiment. Freeze dried melanin was mixed with PBS or citrate buffer to form a 
2 mg/ml suspension. The suspension was sonicated for 15 minutes before incubation 
with the test compounds. Test compound solutions were prepared from 50 mM stock 
solutions stored at -20 ºC. 
 
Kinetic studies were performed with nadolol, timolol, methotrexate, dexamethasone 
and CDCF at a melanin concentration of 0.5 mg/ml and with nadolol and chloroquine at 
1 mg/ml. CDCF was studied at 0.1 µM concentration and the other compounds at 1 µM, 
due to limitations of the analysis method, ultra performance liquid chromatography 
(UPLC). 75 µl of compound solution was added to 75 µl of melanin suspension 
(1 mg/ml or 2 mg/ml) in eppendorf tubes and incubated in a shaker (220 rpm) at 37 ºC. 
The time points were 1, 3, 5 or 6 and 21 hours, with three replicates for each time point. 
Control samples (three replicates) were incubated in PBS without melanin. After the 
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incubation, the eppendorf tubes were centrifuged at 17 000 g for 15 minutes. The 
supernatant was collected for UPLC analysis. 
 
Equilibrium binding studies with a concentration range of 0.25-500 µM (n=11) were 
performed for all the compounds. The binding was measured at a time point where 
equilibrium of binding was reached. 20 hours was chosen due to experiment scheduling 
and to guarantee the equilibrium state. The concentration of the prepared melanin 
suspension was 2 mg/ml. 70 µl of compound solution was added to 70 µl of melanin 
suspension, and incubated as in kinetic studies for 20 hours. Controls were prepared 
with 70 µl of PBS instead of melanin suspension. Number of replicates was three. The 
experiments were performed on Skirted 96 well PCR plates with removable 8-strip Flat 
Caps (4titude, Wotton, Surrey, UK). After the incubation the well plates were 
centrifuged at 1800 g for 4 minutes, to remove the condensed water from the caps to the 
solution in the wells. The contents of the wells were then moved to eppendorf tubes and 
treated as previously in the kinetic study. 
 
Dissociation studies were performed at 1 µM and 10 µM concentrations of nadolol, 
timolol and chloroquine at a melanin concentration of 1 mg/ml. 50 µl of compound 
solution was added to 50 µl melanin suspension (2 mg/ml) in an eppendorf tube. The 
binding was allowed to reach equilibrium, after which the melanin-compound mixture 
was diluted 1:20 with PBS to initiate dissociation. Incubation conditions were the same 
as in previous experiments. Dissociation of bound compound into the PBS solution was 
measured until 24 hours (n=9) and for chloroquine also at 120 hours (5 days). 100 µl 
samples were taken at each time point. 
 
An association study was performed with nadolol at concentrations 1 and 10 µM. 
700 µl of compound solution was added to 700 µl of melanin suspension (2 mg/ml) in 
eppendorf tubes and incubated at 37 ºC. 100 µl samples were taken between 15-
300 minutes (n=8), with manual shaking of the tube before sample taking. Control 
samples were incubated without melanin, and samples were taken at 0, 180 and 
300 minutes. Number of replicates was again three. 
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Table 6. Binding studies performed. 
  Melanin binding studies       
Compound Kinetics Equilibrium Dissociation Association 
  (melanin conc. (mg/ml)) pH 7.4 pH 5     
Timolol 0.5 yes - yes - 
Nadolol 0.5 and 1 yes - yes yes 
Chloroquine 1 yes - yes - 
Methotrexate 0.5 yes yes - - 
CDCF 0.5 yes yes - - 
Dexamethasone 0.5 yes - - - 
Experimental melanin concentration 1 mg/ml if not otherwise indicated. 
 
6.2.4 Sample analysis 
 
Samples with concentrations over 0.1 µM were analyzed with UPLC (Aquity UPLC, 
Waters, Milford, MA, USA) with UV detection (Photodiode Array Detector, Waters, 
USA). The separation was carried out on a UPLC HSS T3 (1.8 µm, 2.1 x 50 mm) 
column (Waters, USA) at 30 ºC. Injection volume was 10 µl. Gradient mode was used 
for all the compounds with acetonitrile/15 mM phosphate buffer (pH 2) mobile phase. 
Gradient duration was 3-5 minutes depending on the sample. 
 
For the samples with less than 0.1 µM of the studied compound, a mass spectrometric 
analysis with UPLC separation was used. The liquid chromatography instrument was 
Waters Aquity UPLC (Waters, Milford, MA, USA). The separation was carried out on a 
Waters UPLC HSS T3 (1.8 µm, 2.1 x 100 mm) column at 25 ºC. Injection volume was 
0.5 µl. Gradient mode was used with acetonitrile (0.1 % formic acid)/water (0.1 % 
formic acid) mobile phase. For nadolol, the water solvent had no formic acid. Mass 
spectrometric measurements were carried out using Waters Xevo TQ-S triple 
quadrupole mass spectrometer with electrospray ionization with negative mode for 
CDCF and positive mode for the other compounds. Propranolol was used as an internal 
standard. 
 
For the equilibrium study with CDCF, fluorescence analysis was performed on a 
VarioskanFlash (Thermo Scientific, Waltham, MA, USA) fluorescence plate reader 
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with 510 nm excitation and 535 nm emission. Samples were diluted 1:10 with 0.1 M 
sodium hydroxide before analysis. 
 
If not analyzed on the same day, samples were stored at -20 ºC until analysis. Samples 
were also prepared of melanin incubated with PBS (without any test compounds) and 
treated as test samples to evaluate the effect of melanin on the analyses. 
 
6.2.5  Calculation of the binding parameters 
  
As done in melanin binding studies in general, the binding was assumed to be analogous 
to the adsorption of a compound on a solid (Pitkänen 2007; Cheruvu et al. 2008). Thus 
the results of the equilibrium study were fit in a Langmuir binding isotherm for one 
(Equation 2) and two (Equation 10) binding site classes. The number of binding site 
classes was evaluated with Scatchard plots, Hill plots and the goodness of fit of the 
binding isotherm. Nonlinear curve fitting was performed with SigmaPlot software 
(version 11.0, Systat Software, San Jose, CA, USA) 
 
  
       
      
    (2) 
  
        
       
 
        
       
   (10)
 
where B is the amount of compound (ligand) bound to melanin (nmol/mg), Bmax is the 
maximum capacity for the binding of the ligand (nmol/mg), [L] is the concentration of 
the free compound (µM), and Kd is the equilibrium dissociation constant (µM). 
  
The value for the dissociation rate constant was calculated according to Equation 11: 
 
       
            (11) 
 
where Bt is the amount bound (nmol) at time t (h), B0 is the total amount bound (nmol) 
at time zero, and koff is the dissociation rate constant (h
-1
). 
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Binding was also analyzed with the Hill plot. It is mainly used in receptor binding 
studies and gives an idea of the number of binding site classes and whether there is 
cooperativity between binding sites (Invitrogen 2006). The Hill coefficient is the slope 
of the linear transformation of the Hill equation: 
 
   
 
    
               (12) 
 
where B is the amount of drug bound to melanin (nmol/mg), RT is the total amount of 
binding sites in melanin (nmol/mg), n is the Hill coefficient, L is the free concentration 
of the drug (µM) and Kd is the dissociation constant (µM). The total amount of binding 
sites in melanin is not known, so different values starting from the calculated Bmax 
values were used. The Hill coefficient values were interpreted according to Table 7. 
 
Table 7. The interpretation of Hill coefficients (Invitrogen 2006). 
Hill coefficient Interpretation       
1 One class of binding sites       
< 1 One class of binding sites, negative cooperativity 
 
1 < n < 2 One class of binding sites, positive cooperativity 
 
 
or two classes of binding sites, negative cooperativity 
2 Two classes of binding sites     
 
 
6.3 Cell study with porcine RPE cells 
 
6.3.1 Isolation of RPE cells from porcine eyes 
 
The RPE cells used for the cell uptake study were isolated from porcine eyes. Fresh 
porcine eyes were obtained from a slaughter house (HK Ruokatalo, Forssa). During 
transport the eyes were kept in ice. Extraocular material was cleaned from the eyes with 
scissors, the eyes were dipped in ethanol and placed in PBS until all eyes were cleaned. 
20 eyes were used to fill one T25 cell culture flask (Sarstedt, Nümbrecht, Germany). 
Two T25 bottles of cells were used for the study, thus isolation of the cells was done 
twice.  After the cleaning, the eyes were managed in batches of five. The anterior part of 
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the eye with the vitreous was removed in the same manner as in the isolation of 
melanin. The eye cup was then filled with PBS (without CaCl2 and MgCl2) which was 
removed after 10 minutes. The neural retina was carefully removed with tweezers. The 
eye cups were filled with 0.25 % trypsin-EDTA and incubated for 30 minutes at 37 ºC 
in a humidified atmosphere with 5 % CO2. The detached cells in the trypsin-EDTA 
solution were collected into 50 ml centrifuge tubes and twice the volume of the trypsin-
EDTA-cell solution of growth medium (10 % (v/v) fetal bovine serum, 1 % penicillin-
streptomycin in D-MEM 31885) was added. The tubes were centrifuged three times; 
first at 450 g for 5 minutes, then twice at 200 g for 2 minutes, in between replacing the 
supernatant with growth medium. The cells were suspended again in medium and 
transferred to the cell culture bottle. 
 
6.3.2 Cell culture 
 
Medium for the pRPE cells in the cell culture bottle was changed twice a week. The 
cells were seeded on a 48-well plate (Nunclon™ Delta surface, 1.1 cm2/well, Thermo 
Scientific, Waltham, MA, USA) after two to three weeks in the cell culture bottle. The 
cell monolayer was washed with pre-warmed DPBS (without CaCl2 and MgCl2). The 
cells were incubated at 37 ºC (5 % CO2) with 0.25 % trypsin-EDTA for 5 minutes and 
then suspended in growth medium. Cell density was adjusted to 300 000 cells/ml. 
240 µl (ca. 72 000 cells) of cell suspension was added to each well and incubated 
overnight before the experiments. 
 
Cells in the cell culture bottle were observed with a light microscope (Leica, Wetzlar, 
Germany) at days 4, 8 and 14 after the cell isolation and 1 day after seeding on the well 
plate to assure the cells were dividing and contained melanin. 
  
6.3.3 Cell experiments 
 
Compound solutions were prepared aseptically from filter sterilized (Corning
®
 (MA, 
USA) syringe sterile filter with regenerated cellulose membrane, pore size 0.20 µm) 
stock solutions. Stock solutions were prepared in DMSO or Milli-Q water (see 6.2.3 
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Binding study). Final compound solutions were diluted from the stock solutions with D-
MEM 31885. The concentration of DMSO in the final solutions did not exceed 1 %. 
 
Uptake experiments were performed with all the compounds at concentrations 1, 5 and 
10 µM with an incubation time of 20 hours. At 1 µM concentration of nadolol, timolol, 
dexamethasone and chloroquine also time points 1 and 5 hours were studied. With 
efflux substrates chloroquine, methotrexate and CDCF the uptake study was also 
performed at a 1 µM concentration with a general efflux inhibitor probenecid. 
Probenecid concentration was 10 µM, enough to assure efflux inhibition (Mannermaa et 
al. 2009). Time points with the inhibitor were 1, 5 and 20 hours. Elimination studies 
were performed with chloroquine and timolol without the efflux inhibitor and with 
chloroquine, methotrexate and CDCF in the presence of the inhibitor. To reach 
equilibrium before initiating the elimination, the cells were incubated with the 
compound solutions for 20 hours. Time points for the elimination study were 0.5, 1, 2, 
4, 6, 14, and 48 hours. Each experiment was performed in duplicate. Cell studies 
performed are compiled to Table 8. 
 
Table 8. Cell studies performed. 
  Cell studies       
Compound Uptake Uptake Elimination Elimination 
    with inhibitor   with inhibitor 
Timolol yes - yes - 
Nadolol - - - - 
Chloroquine yes yes yes yes 
Methotrexate yes yes - yes 
CDCF yes yes - yes 
Dexamethasone yes - - - 
 
 
Before the experiments, growth medium was removed from the wells and cells were 
washed with pre-warmed DPBS (with CaCl2 and MgCl2). 250 µl of compound solution 
was added to the wells. In the inhibitor studies, the cells were pre-incubated with an 
inhibitor for 15 minutes before adding the compound solution that also included the 
inhibitor. After the incubation time, the solution in the wells was placed in an eppendorf 
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tube and centrifuged at 12 000 g for 1 minute. The supernatant was collected for 
analysis. The cells left in the well were lysed with 150 µl of 0.1 M ammonium 
hydroxide and the suspension centrifuged at 17 000 g for 5 minutes. The supernatant 
was collected for analysis. In the elimination studies, at each time point, 250 µl of 
solution was removed for analysis and replaced with 250 µl of medium (D-MEM 
31885). The cells were lysed after the last time point. 
 
Control samples were incubated on the 48-well plates without any cells. Incubation 
conditions were the same as with the cells. Number of replicates for each sample was 
two. 
 
6.4 Pharmacokinetic modeling 
 
Pharmacokinetic simulation models were built with STELLA
®
 software (Version 9.0.1, 
Isee Systems, Lebanon, NH, USA). Runge-Kutta 4 was used as the integration method 
and the integration interval (DT) was 0.001 h. Melanin binding was assumed to be 
identical to a bimolecular reaction 
 
         
 
where M is free melanin, L is the free binding ligand (drug) and ML is the bound 
melanin-ligand complex. The rate of the melanin-ligand complex formation is depicted 
by Equation 13: 
 
     
  
                        (13) 
 
where the symbols in square brackets express concentration (nmol), M for melanin, L 
for the binding ligand, and ML for the melanin-ligand complex. kon is the association 
rate constant (nmol
-1
h
-1
) and koff  the dissociation rate constant. In the case of the two-
site binding model, both sites are treated according to Equation 13 giving the sum 
 
      
  
 
      
  
                                                     (14) 
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In a pharmacokinetic model, the amounts of ligands are used instead of concentrations. 
Thus both sides of Equation 13 can be multiplied with volume, giving the equation the 
form 
   
  
                    (15) 
 
The association rate constant (kon) was calculated from the equilibrium dissociation 
constant (Kd) and dissociation rate constant (koff): 
 
              (16) 
 
Both melanin binding and cell uptake together with melanin binding were modeled. The 
rate of cell uptake was depicted with Equation 17: 
 
                       (17) 
 
where Papp is the apparent permeability of the cell membrane (dm/h), SA is the surface 
area of the cells (dm
2
), CL is the concentration of the free ligand inside the cells (nM) 
(as L in Equations 13, 14 and 15), and CL,O in the concentration of the ligand outside the 
cells (nM).  
 
Equilibrium binding was modeled with one and two-site binding models for all the 
compounds that bound to melanin and gave reasonable parameter values with both 
equations. Association and dissociation from melanin were modeled with different koff 
values (and calculated kon values, kon = koff/Kd) to see how this affects the equilibrium 
time and dissociation time with the set of studied compounds. The values for maximum 
binding capacity (Bmax) and equilibrium dissociation constant (Kd) were obtained from 
the in vitro binding study. 
 
Cell uptake was modeled with the cell study concentrations 1, 5 and 10 µM with and 
without melanin binding. Values for Papp were obtained from literature. Pitkänen et al. 
(2005) have determined permeability values of RPE-choroid for lipophilic and 
hydrophilic beta-blockers; 0.0036 dm/h for lipophilic ones and 0.00072 dm/h for 
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hydrophilic ones. These values were treated as monolayer permeabilities and converted 
to cell membrane permeability values by multiplying with two. The corresponding Papp 
values for the model were 0.0144 dm/h and 0.00288 dm/h, for lipophilic and 
hydrophilic drugs, respectively. Chloroquine, timolol and dexamethasone were 
considered to be lipophilic and nadolol, methotrexate and CDCF as hydrophilic. 
 
The amount of melanin inside the cells was considered to be 7.5 mg in the RPE-choroid 
based on the analyses of Menon et al. (1992). The volume of the RPE-choroid was 
assumed to be 10 µl (Ranta et al. 2010). Thus the melanin concentration used in the 
model was 750 000 mg/l. The volume of the cells was assumed to be 0.1 µl. 
 
 
7 RESULTS 
 
7.1 Characterization of melanin granules 
 
The melanin granules were weighed after drying. The weights were 98 mg for the first 
batch (51 eyes) and 30 mg for the second batch (26 eyes). The results of the particle size 
measurement are presented in Figure 1. The size is reported as an average diameter 
(µm) and an average polydispersity index. Microscope images showed significant 
aggregation of melanin granules after 20 h incubation; the largest particles in the 20 h 
incubated suspension were in the 100 µm range, as the largest particles in the freshly 
sonicated solution were less than 20 µm and most particles smaller 5 µm 
(APPENDIX 2). Chloroquine seemed to stabilize the granules when observed with the 
microscope, thus the particle size analysis with Zetasizer Nano ZS was performed also 
together with chloroquine. In this analysis there was no significant difference in the 
particle sizes (Figure 8).  
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Figure 8. Particle size measurement of 0.1 mg/ml melanin suspension and melanin (0.1 
mg/ml) - chloroquine (10 µM) suspension after different incubation times. 
Polydispersity indices are presented inside the bars. (Samples were filtrated after 
incubation with a 5 µm filter.) 
 
Zeta potential measurements were done at pH 5 and 7.4 and of both batches of melanin. 
Zeta potential was slightly lower (more negative) at pH 7.4 (Figure 9). 
 
Figure 9. Zeta potentials of the two isolated melanin batches at pH 5 and 7.4 with the 
standard deviation of three consecutive measurements of the same sample in the 
parentheses. 
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7.2 Binding study 
 
7.2.1 Kinetic study 
 
At 0.5 mg/ml melanin concentration the binding of nadolol and timolol had reached 
equilibrium in 6 hours (APPENDIX 3). Methotrexate did not seem to bind to melanin. 
With CDCF and dexamethasone the results were inconclusive. Ca. 10 % of CDCF 
seemed to bind after 20 hours of incubation. Dexamethasone seemed to bind but the 
time course of binding was unclear. The binding of timolol was between 10-20 % at all 
the time points. Ca. 10 % of nadolol bound to melanin at 0.5 mg/ml melanin 
concentration and 14 % at 1 mg/ml melanin concentration. Ca. 99 % of chloroquine 
bound to melanin. At 1 mg/ml melanin concentration nadolol reached the equilibrium 
state by the 5 h time point and chloroquine already by the 1 h time point. 
 
7.2.2 Equilibrium study 
 
The results for the equilibrium binding study are presented in Table 9 and Figure 10. 
Chloroquine had the highest binding, as the kinetic study already showed. Methotrexate 
did not bind at pH 7.4 but at pH 5 had over 70 % binding at the smallest concentrations. 
The amount of bound timolol (11-21 %) was similar to that of nadolol (8-24 %). 
Nadolol had a higher variation in the binding between different concentrations. The 
results were inconclusive with CDCF at pH 7.4, but if any binding happened, it was 
very low. At pH 5 there was ca. 30 % binding at the smallest concentrations. 
Dexamethasone seemed to bind but the binding was rather low, ranging between 4-10 
% with no correlation with the starting concentration. 
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Table 9. Fractions bound to melanin in the concentration range that gave successful 
results. 
Compound Concentration range (µM) Fraction bound (%) 
Nadolol 0.25-500 8-24 
Timolol 1-500 11-21 
Chloroquine 0.25-500 50-99.6 
Methotrexate (pH 7.4) 0.25-500 0-3  
Methotrexate (pH 5) 0.25-500 18-76 
CDCF (pH 7.4) 0.25-500 1-8 
CDCF (pH 5) 0.25-100 11-30 
Dexamethasone 0.25-50 4-10 
 
 
 
Figure 10. Binding of chloroquine, timolol and nadolol at pH 7.4, and methotrexate 
(MTX) and CDCF at pH 5 on a linear scale (upper graph) and on a log-log scale (lower 
graph). Dexamethasone is included in the log-log scale. Error bars show the standard 
deviation of replicate samples and are in most cases encompassed by the symbol. Error 
bars are not presented in the log-log scale. 
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Binding parameters Bmax and Kd were calculated by nonlinear curve fitting to the 
Langmuir binding isotherm. Values for the parameters are presented in Table 10. With 
timolol, only experiments starting from the 1 µM concentration were considered, since 
there was a problem with the samples of the smallest concentrations, showing no 
binding or negative binding. With CDCF, only the experiments up to the starting 
concentration of 100 µM were considered, because of much larger standard deviations 
in the higher concentration experiments and a poor fit to the nonlinear binding isotherm. 
R
2
 values were higher than 0.98 with both binding site models with all the compounds. 
For chloroquine and methotrexate (pH 5) the Scatchard plots showed upward concavity, 
which can indicate multiple classes of binding sites or negative cooperativity (Figure 
11). For nadolol, timolol and CDCF (pH 5) the Scatchard plot was inconclusive. With 
methotrexate (pH 5) the one-site binding model seemed to give more reasonable values 
for the parameters. With chloroquine both models gave acceptable values. With 
dexamethasone no values for the binding parameters were obtained, most likely due to 
fluctuation in the results caused by the low amount of binding. 
 
Table 10.  Binding parameters of nadolol, timolol, and chloroquine at pH 7.4, and 
methotrexate (MTX) and CDCF at pH 5 with standard error in the parentheses. 
 
One-site binding model         
  Nadolol Timolol MTX pH 5 CDCF pH 5 Chloroquine 
Bmax (nmol/mg) 80.0 (5.2) 138 (7) 140 (12) 19.6 (1.3) 271 (12) 
Kd (µM) 437 (50) 471 (38) 204 (38) 47.5 (6.9) 21.2 (4.0) 
      Two-site binding model         
  Nadolol Timolol MTX pH 5 CDCF pH 5 Chloroquine 
Bmax1 (nmol/mg) 1.65 (1.5) 61.5 (9*10
7
) 39.2 (4.2) 11.9 (6.0) 42.7 (2.5) 
Kd (µM) 5.80 (11) 471 (7*10
7
) 33.1 (4.7) 26.7 (13) 0.785 (0.12) 
Bmax2 (nmol/mg) 88.0 (8.9) 76.9 (9*10
7
) 1 240 (2 200) 2,3*10
7
 (2*10
14
) 268 (3) 
Kd (µM) 567 (130) 471 (6*10
7
) 8 440 (17 000) 6.2*10
8
 (4*10
15
) 56.9 (2.8) 
R
2
 values > 0.98 in all cases. 
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Figure 11. Scatchard plots for the binding of chloroquine, methotrexate (MTX) pH 5, 
nadolol, timolol and CDCF pH 5. 
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methotrexate had values lower than one, also indicating one class of binding sites but 
with negative cooperativity in binding. 
  
Table 11. Hill coefficients (n) calculated with different RT values (*Bmax value 
calculated from the equilibrium study results (one-site binding model)). 
 
TIMOLOL   NADOLOL   CHLOROQUINE MTX pH 5   CDCF pH 5   
RT (nmol/mg) n RT (nmol/mg) n RT (nmol/mg) n RT (nmol/mg) n RT (nmol/mg) n 
138* 1,09 80* 0,96 271* 0,75 140* 0,80 19,6* 1,00 
200 1,06 200 0,90 500 0,60 200 0,78 50 0,88 
500 1,02 500 0,88 1000 0,57 500 0,76 100 0,86 
 
 
7.2.3 Dissociation study 
 
Chloroquine dissociation from melanin was measured at 0, 0.5, 1, 1.5, 2, 3.2, 5, 24, and 
120 h (5 days) with starting concentrations 1 and 10 µM. Results are presented in Figure 
12. The results did not give a good estimate of the dissociation rate constant. Fitting the 
nonlinear Equation 11 to the results gave R
2
 values of 0.168 and 0.015 for the 1 and 10 
µM concentrations, respectively. Fitting a linear equation to the results, R
2
 values were 
0.170 and 0.015. 
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Figure 12. Dissociation of chloroquine from melanin with 1 µM (upper graph) and 10 
µM (lower graph) starting concentrations. Error bars show the standard deviation of 
replicate samples. 
 
Nadolol and timolol bound to such a small extent that after dilution of the system to 
initiate dissociation, the small concentration difference between time points could not 
be reliably analyzed by the mass spectrometric analysis used. 
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7.2.4 Association study 
 
The association of nadolol to melanin was measured at time points 15, 30, 45, 60, 90, 
120, 180 and 300 minutes at a melanin concentration of 1 mg/ml. The association was 
so fast that the association constant (kon) was impossible to calculate in this study design 
(Figure 13). 
 
Figure 13. Association of nadolol to melanin with 1 µM and 10 µM concentrations. 
Error bars show the standard deviation of replicate samples. 
 
 
7.3 Cell study 
 
7.3.1 Cell culture 
 
The cells were photographed 4, 8 and 14 days after the isolation and 1 day after seeding 
on the 48 well plate (Figure 14). Melanin granules were visible in all stages, although 
the amount of pigmentation seems to be less in later stages compared to day 4. 
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Figure 14. Microscope images of the second batch of pRPE cells (10x magnification) 4 
(top left), 8 (top right) and 14 days (bottom left) after isolation and 1 day after seeding 
(bottom right) on the well plate. 
 
 
7.3.2 Uptake study 
 
The amount of chloroquine taken up by the cells was substantial. The starting 
concentrations were 0.34, 2.8 and 6.7 µM. An average of 91, 64, and 52 % of 
chloroquine was taken up by the cells at these starting concentrations, respectively. The 
results for the uptake study at time point 20 h are presented in APPENDIX 4. 
 
The amount taken up by the cells was too small for reliable detection with 
dexamethasone, methotrexate, and CDCF from the samples taken from the medium. In 
the studies done with the inhibitor, the cells contained an average of 1.7 % of the total 
methotrexate in the wells and 1.4 % of the total CDCF. The cell study with nadolol was 
unsuccessful, since in the UPLC analysis there was another compound in the medium 
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that eluted at the same time as nadolol, and the amount of nadolol could not be 
quantitated. Due to limitation in the amount of RPE cells, nadolol was left out of 
subsequent experiments. In the case of timolol, it seemed that some of the drug was 
taken up by the cells, but the variation of the results was so large that the result was not 
statistically significant. 
 
7.3.3 Elimination study 
 
The results for the elimination of chloroquine from the cells are presented in Figure 15. 
The presence of probenecid had no significant effect on the results. When compared to 
the values of the uptake study, the amounts left inside the cells after the 48 hour 
elimination study were on average 84 % and 57 % of the amount taken up by the cells 
in the 0.34 and 2.4 µM studies, respectively. 
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Figure 15. Elimination of chloroquine from pRPE cells (squares represent experiments 
without inhibitor, circles with inhibitor (probenecid = I), 1 and 2 are replicate wells). 
 
The results for the elimination of timolol are presented in Figure 16. At both 
concentrations it is evident that the elimination occurred within the 48 h sampling 
period. After the 48 h period, the amount of timolol left in the cells was less than 2.5 % 
of the amount of timolol eliminated (between 0.5 and 48 h). 
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Figure 16. Elimination of timolol from pRPE cells at starting concentrations of 1 and 
4.8 µM (1 and 2 are replicate wells). 
 
The elimination study of CDCF was done in the presence of probenecid to maximize 
the probability of the amount inside the cells being measurable. The uptake in the 
presence of probenecid was rather scarce, since no uptake was detected in samples taken 
from the medium before initiating elimination. The elimination study, however, showed 
that CDCF was taken up by the cells, since elimination could be detected (Figure 17). 
After the 48 h study there was 22 % and 11 % of the amount of CDCF eliminated 
(between 0.5 and 48 h) left in the cells (replicate wells 1 and 2, respectively). 
 
Figure 17. Elimination of CDCF from pRPE cells at a 1 µM starting concentration in 
the presence of probenecid (=I) (1 and 2 are replicate wells). 
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Methotrexate elimination was studied only in the presence of probenecid, since without 
the inhibitor the amount inside the cells was expected to be very small. The elimination 
was nonexistent, most likely because very little of methotrexate was taken up by the 
cells despite efflux inhibition. 
 
7.4 Pharmacokinetic modeling 
 
7.4.1 Modeling of melanin binding 
 
Kinetic models for melanin binding with one or two binding site classes on melanin 
were constructed. Simplified models are presented in Figure 18, the whole STELLA
®
 
models with equations are found in APPENDIX 5. 
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Figure 18. Pharmacokinetic models for melanin binding with one (upper model) and 
two (lower model) binding site classes. 
 
Since no values for the dissociation rate constant were obtained from the binding study, 
the binding was simulated varying this constant. In the two-site binding model, the 
dissociation rate constants were determined to be the same for both sites, since a 
difference in these values changes the amount bound to melanin. 
 
Dissociation rate constants (koff) were determined so that equilibrium was reached 
within 5 hours (Table 12; APPENDIX 6). Changes in koff did not affect the amount 
60 
 
bound to melanin, only the time to equilibrium. Binding curves for both one and two-
site binding models are presented in Figure 19. 
 
Table 12. Values for the dissociation rate constant (koff). 
koff (h
-1
) One binding site Two binding sites 
Timolol 0.6 - 
Nadolol 0.7 0.5 
Chloroquine 0.1 0.2 
MTX (pH 5) 0.5 0.6 
CDCF (pH 5) 0.5 - 
 
 
 
Figure 19. Modeled binding of chloroquine, timolol and nadolol at pH 7.4, and 
methotrexate (MTX) and CDCF at pH 5. 
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Dissociation was modeled with the same dissociation rate constants as equilibrium 
binding (Table 12). The equilibrium was allowed to reach equilibrium without sink 
conditions. The results are presented in Table 13. 
 
Table 13. Modeled dissociation from melanin. 
 
Compound 
Binding 
model 
Starting 
concentration 
(µM) 
Fraction 
dissociated (%) 
Unbound 
concentration 
(µM)* 
Equilibrium 
time (h)** 
koff (h
-1
) 
Nadolol one-site 1 85 0,131 4 0,7 
  
10 85 1,29 4 0,7 
 
two-site 1 70 0,203 4 0,5 
    10 73 1,56 4 0,5 
Timolol one-site 1 77 0,175 5 0,6 
    10 77 1,73 5 0,6 
Chloroquine one-site 1 7 0,067 2 0,1 
  
10 7 0,690 2 0,1 
 
two-site 1 2 0,017 1 0,2 
    10 2 0,200 1 0,2 
MTX (pH 5) one-site 1 59 0,241 4 0,5 
  
10 60 2,38 4 0,5 
 
two-site 1 43 0,245 3 0,6 
    10 44 2,41 3 0,6 
CDCF (pH 5) one-site 1 71 0,205 5 0,5 
    10 72 1,88 5 0,5 
*Unbound concentration is entirely caused by dissociation, i.e. unbound concentration at t=0 is 0, the 
reported concentration is the equilibrium concentration  
**Equilibrium assumed reached when 95 % of the total 'fraction dissociated' has dissociated and 
equilibrium time reported as the hour within which equilibrium is reached 
       
 
7.4.2 Modeling of cell uptake with melanin binding 
 
A cell uptake model with melanin binding was built for both one and two-site binding 
models (Figure 20; APPENDIX 5). The model was simulated with starting 
concentrations 1, 5 and 10 µM with the compounds that bound to melanin (Table 14; 
APPENDIX 7). The model was also simulated without melanin binding. In this case the 
concentrations inside and outside the cells are the same at equilibrium. The fraction 
inside the cells is therefore determined only by the ratio of the volumes of these 
compartments and is not related to the compound in question. Thus important 
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physicochemical properties, including logP and pKa, are not taken into account in the 
model. The fraction of compound inside the cells with this model (without melanin) was 
0.04 %. 
 
 
 
Figure 20. Pharmacokinetic cell models for one (upper model) and two (lower model) 
binding site classes on melanin. 
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Table 14. Modeled results of cell uptake. 
 
Fraction inside the cells at equilibrium (%)   
 Compound 
Starting 
concentration (µM) One-site binding model Two-site binding model 
Nadolol 1 5,2 11 
 
5 5,2 8,6 
  10 5,1 7,3 
Timolol 1 8,1 - 
 
5 8,1 - 
  10 8,0 - 
Chloroquine 1 79 - 
 
5 79 - 
  10 78 - 
MTX (pH 5) 1 17 28 
 
5 17 27 
  10 17 25 
CDCF (pH 5) 1 11 - 
 
5 10 - 
  10 9,4 - 
Fraction inside the cells without melanin: 0.04 % (all compounds) 
 
When a STELLA model is complicated enough, a change in integration interval (DT) 
can change the results. When DT is set to be very small, the system will resemble a 
continuous system (Isee Systems 2010). This is desired in pharmacokinetic modeling. 
However, the smaller the DT, the shorter is the possible length of a simulation. For 
chloroquine, no results were obtained with the model with two binding sites since it was 
not possible to set the integration interval (DT) low enough to assure steady results and 
still be able to reach equilibrium. 
 
 
8 DISCUSSION 
 
8.1 Characterization of melanin granules 
 
Melanin is known to aggregate in solution over time (Pitkänen et al. 2007). The 
microscopical examination of the particle size showed that melanin formed some larger 
aggregates in suspension during the 20 hour incubation. Aggregation may affect the 
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results of binding studies, since the size of the surface area affects the number of 
binding sites available and thus the bound amount (Pitkänen et al. 2007). However, 
aggregation was most significant after 20 hours of incubation, compared to the earlier 
time point at 5 hours. Since melanin binding is rather fast, the compound has time to 
bind before aggregation is considerable. This reduces the effect of aggregation on the 
results. 
 
There is reasonably little information in literature about the zeta potential of melanin. 
Mani et al. (2001) measured the zeta potential of synthetic melanin getting zeta 
potential values of -12 mV (pH 5) and -45 mV (pH 7). These results resemble the 
measured zeta potential of melanin in this study (on average -16 mV (pH 5) and -25 mV 
(pH 7.4)) although there is a significant difference in the near neutral pH results. 
Differences between these studies can however be expected, since synthetic and natural 
melanins are being compared. 
 
A difference in zeta potential at different pH values can be expected to affect melanin 
binding, especially with charged compounds, since it changes the strength of ionic 
interactions. Mani et al. (2001) showed also that proteins bound to melanin change the 
zeta potential of the complex to the more positive direction. Since melanin is always 
bound to proteins in vivo, this is expected to affect melanin-drug binding. However, 
Larsson and Tjälve (1979) have shown that protein moieties bound to natural melanin 
do not affect the characteristics of this binding. More results are needed on this matter. 
 
8.2 Binding study 
 
8.2.1 Experimental conditions 
 
The binding study was done with melanin from porcine RPE-choroid. There are known 
differences between results achieved using melanin from different sources (Koeberle et 
al. 2003; Pitkänen et al. 2007). This affects the comparison of results obtained with 
melanin from different sources and the prediction of drug binding in human RPE-
choroid. Since the availability of human ocular melanin is limited, melanin binding 
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studies are mostly done with isolated bovine, Sepia or porcine melanin or with synthetic 
melanin (Potts 1964; Shimada et al. 1976; Koeberle et al. 2003; Pitkänen et al. 2007; 
Pescina et al. 2012). Using these results as such in prediction of human ocular melanin 
binding may cause some errors. There is little information in literature about differences 
in the structure of melanin from different sources and different isolation techniques. 
Also the composition of the experimental environment (suspension) may affect the 
results, since e.g. metal ions in the suspension are shown to affect the magnitude of 
melanin binding of other compounds by binding to melanin themselves (Wrzesniok et 
al. 2012). More comparative studies with different melanin sources should be performed 
and methods developed to ease the comparison of results from different binding studies. 
For example, the binding should be normalized to the surface area of the melanin 
granules, since surface area affects the amount bound (Pitkänen et al. 2007). In this 
study, the surface area of melanin granules was not analyzed. 
 
The binding studies, other than with methotrexate and CDCF, were done only at 
physiological pH 7.4. The pH of ocular melanosomes is expected to be acidic, thus pH 
is a factor in melanin binding. The results at pH 5 and 7.4 were very different for 
methotrexate and CDCF. At pH 7.4 methotrexate had no binding, but at pH 5 the 
binding reached 75 % at the smallest concentrations. Methotrexate is a dicarboxylic acid 
with pKa values of 4.1 and 3.4. It is virtually entirely in its anionic form at pH 7.4. At 
pH 5, however, some of the molecule is in the neutral form. Thus it is expected that the 
binding of methotrexate changes with the pH, as the neutral form binds more easily with 
melanin, a polyanionic polymer. The pH also affects the structure of melanin and its 
binding sites. Since melanin is polyanionic, the lower the pH, the more binding sites are 
expected to be in a neutral form. The zeta potential measurement showed that there was 
a difference between melanin charges at the two pH values used; the potential being 
more negative in the higher pH. This gives evidence of the changing electrostatic nature 
of the melanin in these pH values. The less negative potential of melanin would further 
ease the binding of methotrexate at pH 5. CDCF, an acid with a pKa of 5.1, showed 
similar behavior at these two pH values. While no binding occurred at pH 7.4, there was 
ca. 30 % binding at the smallest concentrations at pH 5.  
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Melanin binding in vivo is more complex than the mere interaction between melanin 
and the drug. The pH varies in different parts outside and inside the cell. There can be 
metabolism, binding to other cellular components or other kinetic factors (e.g. 
extracellular distribution of the compound) (Larsson 1993). The melanin inside 
melanosomes is covered by a lipid membrane that the drug has to penetrate before it can 
bind. As the pH outside the melanosome is closer to 7.4, the pH difference especially 
affects the permeation of acidic drugs with pKa values lower than 7.4. The binding 
study done at pH 5 would most likely give results that are not reflected in in vivo or cell 
studies, since the drug does not have similar access to the actual melanin. At pH 5 
however the binding study would give a more accurate result of the intrinsic interaction 
between the drug and melanin. In the cell study, the amounts of methotrexate and 
CDCF inside the cells were comparable to dexamethasone, a low binding very weak 
acid (pKa 11.4) that is neutral at both pH values and much less than with chloroquine, a 
strongly binding base (pKa 8.1 and 10.4), that is cationic in both pH values. Thus it 
would seem that the binding result of melanin at pH 5 is not reflected in this cell study. 
However, a negative control was missing, since cells without melanin were not used as 
comparison. This makes it hard to draw reliable conclusions of the effect melanin 
binding has on the cell uptake and cellular kinetics of methotrexate and CDCF. 
 
The decision about the pH in which melanin binding studies are performed should be 
made based on the aims of the study. In situations where the result is expected to only 
depict the intrinsic interaction with the drug and melanin, a lower pH would be more 
accurate. These results could be beneficial in a pharmacokinetic model where the lipid 
membrane of melanosomes is taken into account separately. Based on this study, it 
would seem that the results at pH 7.4 are in relation with the results of the cell study, 
and thus depict the in vivo situation better. However, the material of this study is limited 
and literature on this matter is sparse; therefore more studies on the subject should be 
performed. 
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8.2.2 Results of the binding study 
 
The results of the equilibrium binding study were fitted to a Langmuir binding 
isotherm (Equations 2 and 10). Usually either one or two-site binding model is selected 
based on the Scatchard plot (Buszman and Rozanska 2003; Pitkänen et al. 2007). In 
other studies, however, a decision to use the one-site binding model is made based on 
the principle of using the simplest model that fits (Koeberle et al. 2003; Pescina et al. 
2012). Melanin is a random polymer and different modes of interaction are present in 
the binding process (Larsson et al. 1993; Koeberle et al. 2003). Therefore it is difficult 
to differentiate between separate binding site classes. Most melanin binding studies only 
present results of nonlinear curve fitting to one of the two binding models and do not 
compare the differences between the results given by these models. In this study, the 
results were fitted to both models and compared. There were no distinct differences 
between the goodness of fits, but p-values for the binding parameters varied greatly. 
Scatchard plots were indicating two classes of binding sites for chloroquine and 
methotrexate (pH 5). This shape of a Scatchard plot can also indicate binding with 
negative cooperativity (Invitrogen 2006). Thus the binding was also analyzed with the 
Hill plot. With the other compounds Scatchard plots were inconclusive. In most cases 
the Hill plot gave values close to one, suggesting towards the one-site binding model. 
With chloroquine and methotrexate, however, the Hill coefficient hinted of negative 
cooperativity in binding instead of two separate binding site classes. This kind of 
binding deviates from Clark’s theory of binding, where there should be one ligand 
independently interacting with one receptor with no cooperative binding (Invitrogen 
2006). Deviations from Clark’s theory make it harder to evaluate binding parameters 
with equations like the Langmuir binding isotherm. The Hill equation is mostly used in 
receptor binding, which is very specific in nature (Invitrogen 2006). Melanin binding, at 
least in this study, would seem to resemble nonspecific binding with low affinity, high 
capacity binding sites. Thus it is difficult to assess the accuracy of the Hill equation in 
melanin binding, since melanin binding is somewhat different compared to receptor 
binding. 
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Considering the pharmacokinetic model, the nature of melanin binding (i.e. one-site or 
two-site binding model) is not significantly relevant. The amounts and fractions bound 
at different concentrations are more important. This was modeled with the kinetic model 
constructed of melanin binding, which is discussed later. 
 
As expected based on literature, chloroquine had the strongest binding to melanin of the 
studied compounds. Timolol and nadolol also bound to melanin, as expected (Aula et al. 
1988; Kadam and Kompella 2010). Literature of methotrexate binding was ambivalent, 
with studies reporting either binding or no binding at neutral pH (Tsuchiya et al. 1987; 
Wilczok et al. 1990). At pH 5, binding was expected (Tsuchiya et al. 1987). 
Dexamethasone, as expected, had low binding (European Medicines Agency 2010). No 
results were found on the binding of CDCF, but a closely resembling molecule 6-
carboxyfluorescein did not bind at pH 7.4 (Pitkänen et al. 2007). From this point of 
view, the binding study results were in line with literature. 
 
Variation in the results for the parameters Kd and Bmax between different studies is 
somewhat large (Table 15, timolol). This may be a result of different melanin isolation 
techniques or melanin sources, different assay conditions or even different analytic 
methods (Tsuchiya et al. 1987). Only a few studies with porcine ocular melanin were 
found (Buszman and Rozanska 2003; Buszman et al. 2008; Pescina et al. 2012). These 
studies did not contain any of the compounds of this study. Comparing the values of 
these parameters to other literature is therefore challenging. Results from literature have 
been collected to Table 15. For the compounds in this study, all literature results were 
calculated with the one-site binding model. 
 
  
69 
 
Table 15. Literature values for binding parameters (Bmax, Kd) and experimental values of 
this study analyzed with the one-site binding model. 
 
Compound Parameters This study Literature   
  Bmax (nmol/mg) 138 6,98
1 
233
2 
Timolol Kd (µM) 471 6,00 45,1 
  Melanin porcine Sepia synthetic 
 
Bmax (nmol/mg) 80 8,91
1 
 
Nadolol Kd (µM) 437 6,20 
 
  Melanin porcine Sepia   
 
Bmax (nmol/mg) 271 1130
2 
 
Chloroquine Kd (µM) 21,2 2,35 
   Melanin porcine synthetic   
 
Bmax (nmol/mg) 140 60,0
3 
63,0
3 
Methotrexate (pH 5) Kd (µM) 204 42,7 92,6 
  Melanin porcine synthetic B16 melanoma 
 
Bmax (nmol/mg) 19,6 - 
 CDCF (pH 5) Kd (µM) 47,5 - 
   Melanin porcine -   
Dexamethasone: no results for binding parameters were obtained in this study or found from literature 
1
 (Kadam and Kompella 2010) 
2
 (Ono and Tanaka 2003) 
3
 (Wilczok et al. 1990) literature results obtained at pH 7 
 
From the dissociation study, no useful results were obtained. During the 5 day study 
frame, chloroquine did not seem to dissociate significantly from melanin. Some 
dissociation could be detected by the last time point (5 days). The dissociation of 
chloroquine from melanin is known to be very slow as it can be found in pigmented 
tissues even a year after a single intravenous injection (Larsson 1993). Thus the time 
frame for the study may have been too small to detect dissociation. The stability of the 
study system, however, might be questionable during a longer study, since melanin is 
known to aggregate in solution over time as shown in this study and others (Pitkänen et 
al. 2007). When designing a study to determine the dissociation rate constant, this 
should be taken into account with compounds that dissociate slowly. 
 
The dissociation of compounds that have low binding (less than 25 %) should be 
measured with analytic methods sensitive enough to distinguish the small concentration 
differences that the dissociation of the compound causes. In this study, the mass 
spectrometric method used was not sensitive enough to make this distinction. In 
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dissociation studies, mostly radiolabelled compounds have been used (Aula et al. 1988; 
Aula et al. 1989). 
 
There is very little information available of the dissociation of drugs from melanin. 
Dissociation has mostly been studied in vivo by using autoradiography to assess the 
prevalence of the drug in pigmented tissue after dosing has ended (Bathory et al. 1990; 
Trope et al. 1994). This information would be useful for the pharmacokinetic model of 
binding. 
 
In the association study the association of nadolol to melanin seemed to be so fast that 
it was hard to measure accurately enough to calculate the association rate constant (kon). 
In the kinetic studies performed before the association study, the association seemed to 
be somewhat slower, the equilibrium being reached between 3-5 hours. However, 
defining an exact value for kon is not relevant to the pharmacokinetic binding model, 
since association is a faster process than dissociation. 
 
A correlation between the physicochemical properties of the compounds studied and 
their binding to melanin could be noticed. All basic compounds (timolol, nadolol and 
chloroquine) bound to melanin at pH 7.4. The acidic compounds had either no binding 
(methotrexate and CDCF) or low binding (dexamethasone) at pH 7.4. Chloroquine, the 
most lipophilic of the compounds, had the highest binding and the most hydrophilic 
compounds had the lowest binding (i.e. no binding) at pH 7.4. Since the amount of 
compounds studied was small, quantitative structure property relationships cannot be 
made. 
 
8.3 Cell study 
 
In the cell uptake study only chloroquine seemed to accumulate into the cells. 
Chloroquine is known to strongly bind to melanin and to remain in pigmented tissues 
for long periods of time (Larsson 1993). However, chloroquine is also known to 
accumulate into lysosomes (Schraermeyer 1999). To obtain reliable parameters of the 
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effect melanin binding has on the pharmacokinetics of chloroquine, it would be 
important to have control cells that do not contain melanin. 
 
The elimination of chloroquine seemed to be nonlinear. However, an equilibrium state 
was most likely reached, since the amount of compound eliminated from the cells at 
each time point did not seem to increase although the time between each sample (i.e. 
time point) increased as the study went on. More thorough sink conditions, i.e. more 
frequent medium changes, in the cell elimination studies would have been necessary. 
 
Timolol, another melanin binding drug in the cell study, did not seem to be retained 
inside the cells. The elimination took place within the 48 hour sampling period. 
However, timolol has been shown to accumulate into pigmented ocular tissues, 
especially after prolonged exposure (Salminen and Urtti 1984; Trope et al. 1994). Here 
as well, a negative control of cells without melanin would have helped to evaluate the 
effect melanin had on the elimination phase. 
 
The efflux inhibitor probenecid did not seem to have an effect on the elimination of 
efflux substrates chloroquine, CDCF or methotrexate. The effect on uptake of these 
compounds was left unclear, since there was a problem with the ‘inside the cell’ 
samples in the inhibitor studies. The samples from inside the cells did not have the 
amount of compound expected based on medium samples and mass balance. This may 
be due to a failure in the lysing of the cells. The compound may have been left bound to 
cell components, among others melanin. Human retinal pigment epithelial cell lines are 
expected to express efflux transporters MRP1, MRP4 and MRP5 (Mannermaa et al. 
2009). Porcine RPE has been shown to express P-glycoprotein (P-gp) and MRP1 
(Steuer et al. 2005). Chloroquine and methotrexate are MRP1 and P-gp substrates and 
CDCF an MRP5 substrate. Since efflux expression in the pRPE cells used was not 
studied, the repertoire of efflux transporter expression in these cells is not known with 
certainty. Thus drawing reliable conclusions of the effect of efflux based on this study is 
difficult. Also, a more sensitive analytic method, possibly radiolabeling, should be used 
when assessing the small differences in drug uptake caused by the inhibitor. 
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Some improvements to the cell study design could have been made. Some samples were 
left unanalyzed, since medium samples showed only minor drug uptake. Without 
significant melanin binding, as with chloroquine, the amount taken up by the cells was 
so low, it could not be reliably detected in the medium samples, but could have been 
detected in the cell samples. There may have been some noticeable differences in the 
amounts taken up by the cells left undetected. This, combined with the problems with 
cell samples in the inhibitor and elimination studies, made it difficult to obtain 
parameters for the pharmacokinetic model from this cell study. Also, considering the 
pharmacokinetic model, it would have been beneficial to have a negative control, i.e. 
similar cells without melanin, in the cell studies. This would ease the comparison 
between results from the cell studies and results from melanin binding studies. Knowing 
the effect melanin binding has on cellular pharmacokinetics helps to create a 
pharmacokinetic model of the effect on ocular pharmacokinetics and possibly enables 
the use of a model with parameters from melanin binding studies alone. 
 
8.4 Pharmacokinetic modeling 
 
8.4.1 Melanin binding model 
 
Melanin binding was modeled with both the one and two-site binding models. In the 
one-site binding model the variation of koff did not cause any difference in the amount 
bound to melanin, but changed the time till equilibrium was reached. In the two-site 
binding model, a difference in koff values for the two binding sites caused differences in 
the amount bound to melanin. Thus the values were determined to be the same for the 
separate binding sites. The reality of this situation remains unknown, since there is very 
little information in literature of melanin dissociation rate constants. The few studies 
found depict melanin binding with the two-site binding model but give one value for the 
dissociation constant (Aula et al. 1988; Aula et al. 1989). Thus at this point it is 
informed to use only one value for this constant. 
 
With chloroquine and methotrexate (pH 5) the Scatchard plot could be considered an 
indication of two binding site classes. Therefore, it can be debated whether the one or 
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two-site binding model should be used in the model. When equilibrium binding was 
simulated with both models, it was evident that the two-site binding model gave values 
closer to experimental values, especially with the smaller test concentrations. At the 
higher concentrations the difference between the two models was smaller or 
nonexistent. Since the therapeutic concentrations of ocular drugs are usually not higher 
than 10 µM, it would be important to concentrate on depicting the smaller 
concentrations better (Ferencz et al. 1999; Chang-Lin et al. 2011). Thus it might be 
unnecessary to perform binding experiments with concentrations as high as was done in 
this study. The binding results of the higher concentrations seemed to distort the binding 
equation so that it gave less accurate values for the smaller, and from a therapeutic 
viewpoint more important, concentrations. 
 
The modeled dissociation from melanin was rather fast. The modeled results, especially 
in the case of the equilibrium time, may not depict the real situation, since no values for 
koff were obtained from the binding study. Chloroquine, which is expected to dissociate 
slowly, seemed to dissociate quite rapidly since a somewhat large koff value was used. 
Chloroquine also reached equilibrium with less than one tenth of the bound amount 
dissociated, therefore the reality of the dissociation process in vivo, where the 
conditions resemble sink conditions, was not depicted. Since there is very little 
information of dissociation rate in literature, the reality of dissociation from melanin in 
vitro remains unknown. 
 
Pharmacokinetic modeling can help in the design of melanin binding and cell studies by 
giving an idea of the expected events in the study. Study concentrations and needed 
incubation times are among the parameters that can be designed more easily with the 
help of kinetic simulations. In the dissociation study with chloroquine, the study time 
frame was thought to be too small (5 days). However, according to the kinetic model, 
this was most likely not the case, since the dissociating chloroquine quickly reaches 
equilibrium where according to the one-site binding model 7 % and the two-site binding 
model 2 % of the bound amount has dissociated. This dissociation causes a 
concentration difference of 67 or 17 nM (1 µM starting concentration) or 690 or 200 nM 
(10 µM). The higher concentration differences could have been detected, but the 
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standard deviations in the dissociation study were so high, that getting statistically 
significant results would have been hard. This shows that creating sink conditions in in 
vitro dissociation studies would be important, especially with high binding compounds. 
Without pharmacokinetic modeling, this conclusion could have been left undiscovered 
in this study. 
 
8.4.2 Cell model 
 
The constructed cell model is a very simple model that does not take into account many 
factors happening inside the cells. Among these are the intracellular distribution of a 
drug, efflux transporters, and melanin being inside lipid membrane covered 
melanosomes. For example, chloroquine is known to accumulate into lysosomes, which 
would significantly affect the cellular kinetics of the drug (Schraermeyer et al. 1999). 
More cell studies should be performed to be able to take these factors into account in 
the model. 
 
Cell uptake results of chloroquine were similar to the simulated results. In the model, 
78-79 % of chloroquine was taken up by the cells with concentrations between 0.3 and 
10 µM. The fraction inside the cells being virtually the same with all the concentrations 
means that the differences in the free concentration inside the cells with the different 
starting concentrations is not large enough to cause a difference in melanin binding. The 
amount of melanin and thus its binding capacity in the model is very large, therefore a 
very large concentration of the drug is needed to cause a change in the fraction bound to 
melanin. In the in vitro cell study the amounts of chloroquine taken up by the cells were 
91 % (0.34 µM), 64 % (2.8 µM) and 52 % (6.7 µM) of the starting amount. Since a 
negative control was missing, it is difficult to evaluate the fraction of these amounts that 
can be accounted to melanin binding. It can be assumed however, that a part of the 
differences in in vitro and simulated results are caused by intracellular distribution of 
chloroquine not taken into account in the model. Differences in these results can also be 
caused by differences in the amount of melanin inside the cells. The amount of melanin 
in the model was evaluated from the amount in human RPE. In the in vitro cell study 
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porcine RPE cells were used, and the cells most likely did not contain as much melanin 
because of cell division with no melanogenesis. 
 
In the simulated model, 5 % of nadolol and 8 % of timolol were taken up by the cells. In 
the in vitro cell study, nadolol was left out of cell experiments, but timolol was studied 
and seemed to be taken up by the cells. The amount of timolol inside the cells was 
unclear, but some uptake could be detected in the medium samples of the uptake study 
and also in the elimination study. It is possible that the in vitro result would be in line 
with the modeled result but again reliable conclusions cannot be drawn because of 
incomplete in vitro results and lack of negative control. 
 
When using the binding parameters at pH 5, the simulated amounts of methotrexate and 
CDCF taken up by the cells were 17 and 10 %, respectively. In the in vitro cell studies, 
no uptake was detected with methotrexate and the uptake of CDCF was very low. Thus 
it seems the simulated results do not correlate with the in vitro results. This indicates 
that the binding study results obtained at the lower pH do not depict the situation with 
cells and thus the in vivo situation. This is most likely due to the limited access of these 
hydrophilic compounds to the cells. 
 
Elimination from the cells was not simulated, since no useful dissociation or 
elimination parameters were obtained from the in vitro studies. The elimination in the 
model would have therefore been a relatively fictitious situation, since in the model the 
rate of elimination was described only by the dissociation rate constant (koff) and cell 
membrane permeability (Papp). 
 
In the cell model, the only parameters determining the amount of drug inside the cells 
were the maximum binding capacity (Bmax) and equilibrium dissociation constant (Kd) 
obtained from the binding study. This model is too simple for accurate evaluation of 
cellular pharmacokinetics, but gives an idea of the effect melanin binding can have. 
When constructing a more accurate model of the effect of melanin binding, the 
constants above should have an important role, if the desired result is be to be able to 
evaluate cellular pharmacokinetics based on binding study results alone. Considering 
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the large differences of results in different binding studies, it is important that the 
parameters are obtained from studies with same experimental conditions (melanin 
source, isolation technique) or are somehow normalized to correlate better with each 
other. 
 
8.5 Future perspectives 
 
Although melanin binding has been studied widely, there are factors left to be 
determined in the field, especially considering pharmacokinetic modeling. As 
mentioned earlier, there is rather little information in literature about drug dissociation 
from melanin. It would be important to study dissociation rate constants more widely, 
and determine how much of the retention of drugs inside melanocytes can be accounted 
for by retention in melanin. Considering pharmacokinetic modeling, the dissociation 
rate constant would also be important to know, as well as the correlation between 
calculated (kon=koff/Kd) and measured association rate constants (kon). 
 
Since differences in experimental conditions, including melanin isolation methods and 
different sources of melanin, can affect the results of melanin binding studies, it would 
be relevant to do comparative studies to elucidate the factors causing these differences. 
A way to compare results obtained in different conditions could be relating binding 
parameters to the surface area of melanin (Pitkänen et al. 2007). There is rather little 
information of this in literature, therefore more experiments should be conducted on the 
matter. 
 
More studies of melanin binding in cells are needed. There are very few results on 
quantitative uptake of drugs into melanin containing cells. Studying the binding in cell 
cultures would help to relate binding study results done with melanin to the in vivo 
situation. 
 
Melanin binding has not been included in detail into pharmacokinetic models of the eye 
and ocular drug delivery (Ranta and Urtti 2006; Ranta et al. 2010). The model built in 
this study was a very simple cell level model and did not take into account many factors 
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relevant to cellular pharmacokinetics. More information is needed for a more 
comprehensive model and for the inclusion of a cell model to a wider drug delivery 
model. Relating the physicochemical properties of a drug to melanin binding more 
accurately than already done would help in the modeling. In general, more 
comprehensive models of melanin binding are needed, to ease the evaluation of melanin 
binding in drug discovery and possibly take advantage of the binding in drug design. 
 
 
9 CONCLUSIONS 
 
Melanin binding of drugs is an important matter to consider in drug delivery. The 
binding is known to affect the pharmacokinetics of drugs especially in the eye because 
of densely pigmented tissues, like the RPE and iris. The physicochemical properties of a 
drug affect its melanin binding, as shown in this study and others. Although melanin 
binding has been studied numerously in vivo and in vitro, no comprehensive 
quantitative or pharmacokinetic models of melanin binding have been constructed. The 
results of in vitro binding studies and cell studies can be used in a pharmacokinetic 
compartmental model, however much more results are needed to construct a 
comprehensive model. A method for a better comparability of binding study results 
from different studies obtained with different sources of melanin and different study 
conditions should be created and variation causing factors should be determined. This 
would ease the use of these results in modeling as well as the comparison of melanin 
binding of different compounds. The kind of cellular level pharmacokinetic model 
constructed in this study, although a very simple model, has not been published before. 
To further improve this model, it should be modified to take into account many 
important factors affecting cell level kinetics.   
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APPENDIX 1. Formulations of PBS and citrate buffer. 
 
PBS pH 7.4 
 
Per 100 ml of PBS: 
21.0 mg of Potassium Phosphate monobasic (KH2PO4) 
0.900 g of Sodium Chloride (NaCl)  
72.6 mg of Sodium Phosphate dibasic (Na2HPO4-7H2O)  
 
Citrate buffer pH 5 
 
Per 100 ml: 
20.5 ml of 0.1 M solution of citric acid (i.e. 21.0 g in 1 L) 
29.5 ml of 0.1 M solution of sodium citrate (29.4 g C6H5O7Na3-2H2O in 1 L) 
 
  
  
APPENDIX 2. Microscope images of melanin granules in suspension. 
 
  
Light microscope images of a freshly sonicated 1 mg/ml melanin suspension (left) and a 
20 h incubated melanin suspension (right). The scale is the same in both images. 
 
5 h incubated 0.2 mg/ml melanin suspension. The scale is the same as in the upper 
images. 
  
  
APPENDIX 3. Results of the kinetic study.  
 
Kinetic studies were performed to determine the time it takes to reach equilibrium. 
Melanin concentrations used were 0.5 mg/ml and 1 mg/ml. The concentrations of the 
drugs were 0.1 µM for CDCF and 1 µM for the other drugs. 
 
Time to equilibrium 
Melanin concentration 0.5 mg/ml 
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APPENDIX 4. Cell uptake of chloroquine. 
 
Chloroquine uptake study results after 20 h incubation and the mass balance for each 
well. 
 
Wells 
1µM well 
1 
1 µM well 
2 
5 µM well 
1 
5 µM well 
2 
10 µM well 
1 
10 µM well 
2 
Starting concentration (µM) 0,337 0,337 2,77 2,77 6,73 6,73 
Starting amount (pmol) 84,3 84,3 693 693 1681 1681 
Inside (pmol) 80,9 72,0 430 453 872 879 
Inside (%) 96,0 85,5 62,1 65,4 51,9 52,3 
Outside (pmol) - - 116 91,8 407 402 
Outside (%) - - 16,8 13,2 24,2 23,9 
Total (pmol) 
  
546 545 1279 1281 
% from original 
  
78,9 78,7 76,1 76,2 
 
 
  
  
APPENDIX 5. STELLA
®
 models. 
 
MELANIN BINDING MODELS 
 
Equilibrium binding 
 
One-site binding model 
 
 
Equations: 
 
Bound(t) = Bound(t - dt) + (Association - Dissociation) * dt  
Unbound(t) = Unbound(t - dt) + (Dissociation - Association) * dt  
 
INITIAL Unbound = Initial_conc * V_solution 
 
Association = k_on * C_free_melanin * Unbound  
Dissociation = k_off * Bound 
 
Unbound = Initial_conc * V_solution  
Amount_melanin = Conc_melanin * V_solution  
Bmax_calc = Bmax_per_mg * Amount_melanin  
C_bound = Bound / V_solution  
C_free_melanin = ( Bmax_calc / V_solution ) - C_bound  
C_unbound = Unbound / V_solution  
k_on = k_off / Kd 
 
Conc_melanin = 1000 
V_solution = 0.00014 
  
  
Two-site binding model 
 
 
 
Equations:  
 
Bound_1(t) = Bound_1(t - dt) + (Asso_1 - Disso_1) * dt 
Bound_2(t) = Bound_2(t - dt) + (Asso_2 - Disso_2) * dt 
Unbound(t) = Unbound(t - dt) + (Disso_1 + Disso_2 - Asso_1 - Asso_2) * dt 
 
INITIAL Unbound = Initial_conc * V_solution 
 
Asso_1 = k_on_1 * C_free_melanin_1 * Unbound 
Disso_1 = k_off_1 * Bound_1 
Asso_2 = k_on_2 * C_free_melanin_2 * Unbound 
Disso_2 = k_off_2 * Bound_2 
 
Amount_melanin = Conc_melanin * V_solution 
Bmax_calc_1 = Bmax_per_mg_1 * Amount_melanin 
Bmax_calc_2 = Bmax_per_mg_2 * Amount_melanin 
C_bound_1 = Bound_1 / V_solution 
C_bound_2 = Bound_2 / V_solution 
C_free_melanin_1 = ( Bmax_calc_1 / V_solution ) - C_bound_1 
C_free_melanin_2 = ( Bmax_calc_2 / V_solution ) - C_bound_2 
C_unbound = Unbound / V_solution 
  
k_off_1 = k_off 
k_off_2 = k_off 
k_on_1 = k_off_1 / Kd_1 
k_on_2 = k_off_2 / Kd_2 
 
Conc_melanin = 1000 
V_solution = 0.00014 
 
 
Dissociation from melanin 
 
One-site binding model 
 
 
 
Equations (only the ones that are in addition to the equilibrium binding model): 
 
INITIAL Bound = Bound_calc 
INITIAL Unbound = 0 
 
Bound_calc = Bmax_calc * C_unbound_equilibrium / ( Kd + C_unbound_equilibrium ) 
 
 
 
  
  
Two-site binding model 
 
 
Equations (only the ones that are in addition to the equilibrium binding model): 
 
INITIAL Bound_1 = Bound_1_calc 
INITIAL Bound_2 = Bound_2_calc 
INITIAL Unbound = 0 
 
Bound_1_calc = Bmax_calc_1 * C_unbound_equilibrium / ( Kd_1 + 
C_unbound_equilibrium ) 
Bound_2_calc = Bmax_calc_2 * C_unbound_equilibrium / ( Kd_2 + 
C_unbound_equilibrium ) 
 
 
  
  
CELL MODELS 
 
Uptake 
 
One-site binding model 
 
 
Equations (only the ones that are in addition to earlier models): 
 
Outside_the_cells(t) = Outside_the_cells(t - dt) + (Elimination - Uptake) * dt 
INITIAL Outside_the_cells = Initial_C_outside * V_outside 
 
Elimination = P_app * Surface_area * ( C_unbound - C_outside ) 
Uptake = P_app * Surface_area * ( C_outside - C_unbound ) 
Unbound(t) = Unbound(t - dt) + (Dissociation + Uptake - Association - Elimination) * 
dt 
 
Amount_melanin = Conc_melanin * V_cells 
C_outside = Outside_the_cells / V_outside 
C_unbound = Unbound / V_cells 
 
Conc_melanin = 750000 
Surface_area = 0.011 
V_cells = 0.0000001 
V_outside = 0.00025 
 
 
 
  
  
Two-site binding model 
 
 
 
Equations (only the ones that are in addition to earlier models): 
 
Outside_the_cells(t) = Outside_the_cells(t - dt) + (Elimination - Uptake) * dt 
INITIAL Outside_the_cells = Initial_C_outside * V_outside 
 
Unbound(t) = Unbound(t - dt) + (Disso_1 + Disso_2 + Uptake - Asso_1 - Asso_2 - 
Elimination) * dt 
 
 
  
  
Elimination 
 
One-site binding model 
 
 
Equations (only the ones that are in addition to earlier models): 
 
INITIAL Bound = Bound_calc 
INITIAL Outside_the_cells = 0 
INITIAL Unbound = 0  
  
 
Two-site binding model 
 
 
 
Equations (only the ones that are in addition to earlier models): 
 
INITIAL Bound_1 = Bound_1_calc 
INITIAL Bound_2 = Bound_2_calc 
INITIAL Outside_the_cells = 0 
INITIAL Unbound = 0 
  
  
APPENDIX 6. Melanin binding model: time course of binding. 
 
Modeled time course of melanin binding with concentrations 0.25, 0.5, 1, 2.5, 5, 10, 25, 
50, 100, 250 and 500 µM (from 1 to 11 in the graphs, respectively). 
 
One-site binding model 
 
 
 
Timolol, koff = 0.6 h
-1
 
 
 
 
Nadolol, koff = 0.7 h
-1
 
 
13:03    9. jouta 2013
Timolol, one binding site model
Page 2
0.00 2.50 5.00 7.50 10.00
Hours
1:
1:
1:
0.0
0.5
1.0
Fraction bound: 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 - 11 - 
13:13    9. jouta 2013
Nadolol, one binding site model
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Chloroquine, koff = 0.1 h
-1
 
 
 
 
Methotrexate (pH 5), koff = 0.5 h
-1
 
 
 
 
CDCF (pH 5), koff = 0.5 h
-1
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Chloroquine, one binding site model
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Methotrexate (pH 5), one binding site model
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CDCF, one binding site model
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Two-site binding model 
 
 
 
Chloroquine, koff = 0.2 h
-1
 
 
 
 
Nadolol, koff = 0.5 h
-1
 
 
 
 
Methotrexate, koff = 0.6 h
-1
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Chloroquine, two binding site model
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Nadolol, two binding site model
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Methotrexate (pH 5), two binding site model
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APPENDIX 7. Cell model: uptake. 
 
Cell model: fraction outside the cells with starting concentrations 1, 5 and 10 µM (1 to 3 
in the graphs, respectively). 
 
 
 
 
Timolol with one binding site. 
 
 
 
 
Nadolol with one binding site. 
 
18:32    9. jouta 2013
Cell model, timolol with one binding site
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Cell model, nadolol with one binding site
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Nadolol with two binding sites. 
 
 
 
Chloroquine with one binding site. 
 
 
 
Methotrexate (pH 5) with one binding site. 
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Cell model, nadolol with two binding sites
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Cell model, chloroquine with one binding site
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Cell model, methotrexate (pH 5) with one binding site
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Methotrexate (pH 5) with two binding sites. 
 
 
 
CDCF (pH 5) with one binding site. 
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Cell model, methotrexate (pH 5) with two binding sites
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Cell model, CDCF (pH 5) with one binding site
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